UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
10-K
(Mark
One)
☒ ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For
the fiscal year ended: September 30, 2014
Or
☐ TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For
the transition period from ____________ to ____________
Commission
file number: 000-31469
Medical
International Technology, Inc.
(Exact
name of registrant as specified in its charter)
| Colorado |
|
84-1509950 |
(State
or other jurisdiction of
incorporation
or organization) |
|
(I.R.S.
Employer
Identification
No.) |
1872
Beaulac, Ville Saint-Laurent
Montreal,
Quebec, Canada HR4 2E7
(Address
of principal executive offices)(Zip Code)
Registrant’s
telephone number, including area code: (514) 339-9355
| Securities
registered pursuant Section 12(b) of the Act: |
| |
|
|
| Title
of each class: |
|
Name
of each exchange on which registered: |
| None |
|
None |
| |
| Securities
registered pursuant Section 12(g) of the Act: |
| |
Common
Stock, par value $.001
(Title
of class) |
Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒
Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file
such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ No ☒
Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter)
during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☐ No ☒
Indicate
by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this
chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy
or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☒
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller
reporting company” in Rule 12b-2 of the Exchange Act.
| Large
accelerated filer ☐ |
Accelerated
filer ☐ |
Non-accelerated
filer ☐ |
Smaller
reporting company ☒ |
(Do
not check if a smaller reporting company)
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒
The
aggregate market value of the voting and non-voting common equity held by non-affiliates as of September 30, 2014 is approximately
$2,095,115 (based on its reported last sale price by the OTC Bulletin Board).
The
number of shares outstanding of the registrant’s common stock as of November 16, 2015 is 84,304,627
Table
of Contents
CAUTIONARY STATEMENT
RELATED TO FORWARD LOOKING STATEMENTS
This
Annual Report on Form 10-K (this “Report”) contains “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Exchange Act.
Forward-looking statements discuss matters that are not historical facts. Because they discuss future events or conditions, forward-looking
statements may include words such as “anticipate,” “believe,” “estimate,” “intend,”
“could,” “should,” “would,” “may,” “seek,” “plan,” “might,”
“will,” “expect,” “predict,” “project,” “forecast,” “potential,”
“continue” negatives thereof or similar expressions. These forward-looking statements are found at various places
throughout this Report and include information concerning possible or assumed future results of our operations; business strategies;
future cash flows; financing plans; plans and objectives of management; any other statements regarding future operations, future
cash needs, business plans and future financial results, and any other statements that are not historical facts.
From
time to time, forward-looking statements also are included in our other periodic reports on Forms 10-Q and 8-K, in our press releases,
in our presentations, on our website and in other materials released to the public. Any or all of the forward-looking
statements included in this Report and in any other reports or public statements made by us are not guarantees of future performance
and may turn out to be inaccurate. These forward-looking statements represent our intentions, plans, expectations, assumptions
and beliefs about future events and are subject to risks, uncertainties and other factors. Many of those factors are
outside of our control and could cause actual results to differ materially from the results expressed or implied by those forward-looking
statements. In light of these risks, uncertainties and assumptions, the events described in the forward-looking statements might
not occur or might occur to a different extent or at a different time than we have described. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date of this Report. All subsequent written and oral
forward-looking statements concerning other matters addressed in this Report and attributable to us or any person acting on our
behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this Report.
Except
to the extent required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result
of new information, future events, a change in events, conditions, circumstances or assumptions underlying such statements, or
otherwise.
To
Our Shareholders
The
future of our Corporation has always been our key priority and at the core of our considerations from the start of the Corporation.
From quarter to quarter we reassess our positioning in our different markets with each of our distributors and agents we have
nationally and internationally, thereafter we take the decisions we deemed the most accurate for the Corporation to gradually
improve its results and achieve growth within the medium term. The technological advances we have achieved over the past years
in our Needle-Free jet injector market segment firmly places us as the most advanced devices on the market combining speed, regulated
pressure, dosage/volume adjustability and accuracy to produce the most efficient method of drug delivery.
From
the start of our business and to facilitate its rapid market penetration MIT is developing strategic alliances with distributors
and agents per Country that have established a successful distribution network in each of the niche market where MIT products
can be sold. MIT has developed, during the past several years, distribution networks in a few countries. MIT selects its distributors
with the goal of building long-term relationships to ensure the success of MIT’s Needle-Free Injectors.
In
our last year end financials (2013) we explained the benefits and the disadvantages of such a business model working with distributors.
“The disadvantages are when the distributor for different reasons being political, economical or personnel could not perform
as expected resulting in loss of sales and profits.”
During
the year 2014 we have been in disadvantaged situation as some of our distributors did not perform as per our expectations, mainly
because of their economic situations, resulting in decreases in our consolidated revenues of $425,487 or 50 % in comparison to
fiscal year 2013 of $846,782.
Our
Russian Distributor, who after making their first order which was paid for and shipped, had to put a hold on all scheduled sales
after the Ukraine war started. As a result no product has been sold to our Russian distributor.
Other
economic and private situations happened in other countries, South Korea and Mexico, to name few. Our Chinese partners had many
delays in obtaining different certifications and price index in the province in which they had applied, resulting in loss of sales
and orders to MIT Canada. This situation persisted during the entire year and impacted both revenue and cash flow throughout the
year. At the same time, we have continued to focus on carefully managing our fixed operating expenses, making our 2014 year sales
very difficult and stressful.
We
continue to believe that our marketing policy and strategy this year and in the future is to continue the search for distributors
in different markets with the following criteria in place to become an MIT distributor:
| ● | Strong
marketing and sales team. |
| ● | Understanding
MIT technologies and have a medical team. |
| ● | A
strong technical support team. |
We
continue to believe the importance of providing adequate support to our distributors as we expand our network in order to increases
sales. The Company could not establish an internal marketing representative to provide support for its distributors for financial
reasons; the management and the operation director has regularly assisted our network of distributors in their marketing activities
by training the distributor’s sales representatives via video-conferences, providing support for after-sales service, making
regular visits, be present at certain important national and international exhibitions or presentations to potential buyers. In
addition, MIT’s main priority has and always will be its customer satisfaction.
MIT’s
marketing and sales strategies in the medium and long term are the following:
| ● | Conduct
more trials with renowned doctors to respond to new needs in the medical community. |
| ● | Hire
and train qualified marketing representatives with international experiences. |
| ● | Searching
for new dynamic and experience distributors worldwide. |
New
products for 2015:
MIT
will introduce in the second and third quarter of 2015 two new products:
| 1. | MED-JET
MIT H-4 will target all vaccination clinics, hospitals, and many other departments that
have needs for single use disposable cartridge biologic injections. |
| 2. | MINI-JET
for day old chick vaccination in hatcheries. |
| ● | The
first new product MED-JET MIT H-4 will be used in different market for human vaccination
and other medications in different countries including Africa, Asia and the Middle East. |
| ● | The
second new product MINI-JET will be introduced in different market for day old chick’s
vaccination in different countries including USA, Canada, Europe, Africa, Asia and the
Middle East. |
These
two new products should help the Company increase its sales with our existing distributors and new potential agent and distributors
in different countries that are in negotiation for a potential agreement.
Publications
issued in 2013:
| ● | Selection
of Safe Parameters for Jet Injection of Botulinum Toxin in Palmar Hyperhidrosis Aesthetic
Surgery Journal February 2013 33: 295-297,http://www.sagepublications.com/ |
| ● | THE
ART OF INJECTING RE-INVENTED: THE FUTURE OF DRUG DELIVERY IS HERE NOW, Copyright ©
2013 Frederick Furness Publishing Ltd, www.ondrugdelivery.com |
Publications
issued in 2014:
| ● | Treatment
of Nail Psoriasis with Intralesional Triamcinolone Acetonide Using a Needle-Free Jet
Injector: A
Prospective Trial by Melissa Nantel-Battista, Vincent Richer, Isabelle Marcil, and AntranikBenohanian Canadian
Dermatology Association | Journal of Cutaneous Medicine and Surgery, Vol 18, No 1 (January/February), 2014: pp 38–42
|
From
the Department of Dermatology.St.Luc Hospital. Centre Hospitalier de l’Universite´ de Montreal (CHUM), Montreal, QC.
Address reprint requests to: Melissa Nantel-Battista, MD, FRCPC. Department of Dermatology, St. Luc Hospital, CHUM, 264 Rene-Levesque,
Est., Montreal, QC H2X 1P1; e-mail: melissa.nantel-battista@umontreal.ca
DOI
10.2310/7750.2013.13078
PART
I
Item
1. Business
Medical
International Technology, Inc. (“MIT” or the “Company”) was incorporated in the State of Colorado on
July 19, 1999. Our wholly-owned subsidiary, Medical International Technologies (MIT Canada). Inc., a Canadian company, was
acquired in June 2002 and is based in Montreal. We specialize in production, marketing and the sale of needle-free jet
injector products designed for humans and animals applications, for single and mass injections. Needle-free jet injector
technology and products provide advantages over traditional needle injection techniques and products, including; efficiency,
handling security, biological waste elimination, and patient stress reduction.
The
Company concentrates its activities in the medical and para-medical sectors, in particular, in the field of medical devices. Our
strategy is to build a market for its different products and establish strategic alliances with different pharmaceutical companies,
medical devices distributors and manufacturers to ensure good distribution channels for its products.
The
benefits of needle-free injection compared to needle injection, in particular with respect to the features of our products, can
be summarized as follows:
| 1. | Less
tissue damage and less painful; |
| 2. | Simple,
fast and effective; |
| 3. | Precise,
reliable and safe; |
| 4. | Good
absorption of liquids; |
| 5. | Prevents
stress from traditional needle syringes and infections from contaminated needles; |
| 6. | Friendly
to the environment (no biological waste); |
| 7. | Affordable
and economical; and |
| 8. | Efficient
use of medication used. |
General
We
were incorporated in the State of Colorado on July 19, 1999. We had three wholly-owned subsidiaries, Medical International
Technologies (MIT Canada). Inc., a Canadian company acquired in June 2002, 3567940 Canada Inc., a Canadian company, acquired in
June 2002 and merged with MIT Canada Inc. For the past 2 years 3567940 Canada Inc. had no activities, no assets and no liabilities.
In August of 2011 3567940 Canada Inc. was dissolved. In addition, ScanView, a Canadian company acquired in June 2007,
has had no activities for the past several years.
China
Joint Venture and other business development activities
On
May 6, 2009, we entered into a joint venture agreement (the “Joint Venture Agreement”) with Jiangsu Hualan Biotechnology
Ltd. (China) (“Jiangsu Hualan”). Pursuant to the Joint Venture Agreement, the parties established a joint venture
company, Jiangsu Hualan MIT Medical Technology (MIT China) Ltd. (“MIT China”), focusing on research, production and
sales of medical equipment, import and export of medical equipment and components products, especially Needle-Free Jet Injector
products.
The
creation of MIT China in June of 2009 can give MIT a unique advantage to expand its production operations and increase its sales
and profits in the worldwide needle-free injector market. Furthermore, the MIT China venture could help MIT supply large production
volumes in less time, which could attract large medical and pharmaceutical partners.
The
introduction of our Agro-Jet needle-free injector for animal application did not progress as well as believed. Our veterinary
staff has successfully trained our distributors in various regions, and the distributors didn’t market the product as per
our understanding. The Company has re-discussed with our distributors and we now expect that these efforts will result in sales
growth in fiscal year 2015.
During
the third quarter of fiscal year 2011, MIT China purchased 151,000 sq. ft. of land and began construction of our first building
in Taizhou (China Medical City). This first building of 40,000 sq. ft. when finalized will be used for the production of injectors
for the Chinese market only.
Work
in progress at MIT China for the construction of its 40,000 sq. ft. building, the first stage (the offices) has been completed,
and our first move of all our employees to Taizhou was conducted in the beginning of August 2012. The other part of the construction
was scheduled to be completed in the first quarter of 2013/2014 fiscal year, even though our managements and engineers where working
hard to plan the purchasing of the equipment and tools necessary for the assembly and production of some of our Agro-Jet and Med-Jet
products, they were not able to finalize on time. This production facility when finalized should be able to supply a large number
of injectors and disposables to the Chinese market; we expect the production facility to be ready by the first quarter of 2016.
On
November 2011 and per the discussions with our Chinese general manager, Mr. Ethan Sun, our Joint Venture partner, our plan of
sales and expansion into the Chinese market is progressing and MIT China needed more money to expand its operations therefore
MIT China agreed to sell and sold 9% of their joint venture for an investment of 18,000,000 RMB (US$3,000,000). This capital investment
received has reduced the two original partners Jiangsu Jiabo Investment LTD percentage to 46.41% from 51% and MIT Canada to 44.59%
from its 49% and Taizhou Amazon Investment Center, our new partner received 9% ownership in MIT China venture.
In
2012 we have supplied to CDC (Centre of Disease Control) vaccination clinic in China with one Med-Jet model MIT H-III, and requested
an MIT China nurse to be present at the clinic at all times for training, supervision of the proper usage and procedures of our
Med-Jet for vaccination., the results were very good and we have expected more uses of our Med-Jet H-III from many of the CDC
clinics and hospitals across China in fiscal year 2013 which didn’t happen so far, because of the price index that is taking
longtime to receive, we expect to have the price index issue resolved for 2016.
In
2012 we were proceeding positively with our Chinese SFDA for our new Med-Jet model H-4, and in 2013 we added the new product called
DART that uses similar anti-contaminant single use disposable cartridge and we were expecting our certification in the second
quarter of 2013/2014 fiscal year, unfortunately we couldn’t achieve our objective, it is now expected in the Second or third
quarter of 2016.
Our
Model Med-Jet H-4 will target all vaccination clinics, hospitals, all CDC Centers and many other departments that have needs for
single use disposable cartridge biologic injections.
Also
as per the Model Med-Jet H-4, the Model Med-Jet DART, was developed mainly for intra-dermal vaccination and more specifically
for the Polio vaccination in collaboration with a major Chinese pharmaceutical company, the animal protocol trials took place
in China during 2013 and it is now completed, we were expecting the final results and report during the second quarter of 2013/2014.
If the results will be positive and in favor of MIT Canada, we will then be invited to participate in the second and final trial
that will implicate human vaccine trials and will be expected to take place in China and towards the end of year 2014, thereafter
we should expect a major supply agreement to be concluded with the same Chinese Pharmaceutical Company and hopefully many others.
Unfortunately we didn’t receive so far the final results from the Animal study; we are still expecting the final report
to be issued officially in the Second or third quarter of 2016.
Every
year we face with new challenges, in 2014 these challenges were significant and only added to the hurdles we face in trying to
achieve and realize positive results with the above business strategies we have outlined. During 2014, there were some significant
distribution potential agreements, which did not materialize as expected even though there was strong interest in our products.
In addition some of the countries, namely Russia, South Korea and Mexico, to name few, had very bad economical situations in their
respective countries, Our Chinese partners had many delays in obtaining different certifications and price index in the province
they had applied resulting in loss of sale and orders to MIT Canada, furthermore this situation persisted during the entire year
impacted both revenue and cash flow throughout the year, at the same time we have continued to focus on carefully managing our
fixed operating expenses
While
revenues in 2014 were lower than in 2013, we have taken actions related to both revenue and cash management in an attempt to improve
our results. Such actions has included focusing by Mr. Karim Menassa on increasing sales of our devices to our existing and active
distributors and agents, giving them full support in their endeavour to sell our products. We are also exploring new options in
regards to new possible joint ventures in marketing, sales and training centers in collaboration with distributors and doctors
/ nurses.
Our
2014 revenues and results of operations same as previous years have fluctuated and can be expected to continue to fluctuate significantly
from quarter to quarter and from year to year. Various factors may affect quarterly and yearly operating results, including the
following:
| ● | Worldwide
economic situation since we are marketing and selling internationally. |
| ● | The
length of time to close product sales, especially with new distributors. |
| ● | Certification
time line in different markets. |
| ● | Price
index especially in China market. |
| ● | New
product introductions. |
| ● | New
attempt to achieve the US FDA 510K certification taking in consideration the new regulations. |
| ● | Other
unforeseen negative situation worldwide. |
Needle-Free
Injection
All
liquid and non-liquid medications are currently delivered using various methods, each of which has both advantages and limitations.
The
most commonly used drug delivery techniques include oral ingestion, intravenous, subcutaneous, intradermal, and intramuscular
injection, inhalation and transdermal “patch «diffusion. Many drugs are effective only when injected.
Injections
using traditional needle-syringes suffer from many shortcomings, including:
| ● | The
risk of needle sticks injuries. |
| ● | The
risk of penetrating a patient's vein. |
| ● | The
patient’s fear of needles and discomfort. |
| ● | The
contaminated needle. |
| ● | Stress
from needle syringe injections. |
| ● | Infection
from contaminated needles. |
| ● | Biological
waste in the environment. |
| ● | Transmit
deadly blood-borne pathogens including such viruses as HIV and Hepatitis B. |
During
the last decade a growing awareness of the danger of blood-borne pathogen transmission, needle safety has become a big concern
in hospitals, clinics within the healthcare professionals and their patients. As a result, pressure on the healthcare industry
to eliminate the risk of contaminated needle stick injuries has increased, and the U.S. Occupational Safety and Health Administration
(“OSHA”) issued regulations, effective in 1992, which require healthcare institutions to treat all blood and other
body fluids as infectious. These regulations were changed by Congress with passage of the Needle stick Safety Prevention Act,
which was effective in 2001. These regulations require implementing “engineering and work practice controls” to “isolate
or remove blood-borne pathogen hazards from the workplace.” Among the required controls are special handling and disposal
of contaminated “sharps” in biohazard “sharps” containers, safer medical devices, including needle-free
systems, and follow-up testing for victims of needle stick injuries. To date, more than 30 states and the U.S. Occupational Safety
and Health Administration have adopted, or have pending, legislation or regulations that require health care providers to utilize
systems designed to reduce the risk of needle stick injuries.
According
to the International Sharps Injury Prevention Society (http://www.isips.org), it has been estimated that one out of every seven
workers is accidentally struck by a contaminated sharp point each and every year. The Center for Disease Control (CDC: http://www.cdc.gov/niosh/2000-108.html#5)
estimates that there are 600,000 to 800,000 needle stick injuries per year in the U.S. alone, and many are not reported. More
than 20 types of infectious agents have been transmitted through needle sticks, including hepatitis B and C, tuberculosis, syphilis,
malaria, herpes, diphtheria, gonorrhea, typhus and Rocky Mountain spotted fever. The MED-JET will eliminate this risk to health
care professionals and create a safer workplace. Other advantages include its light weight (0.5 kg) and an excellent medication
absorption rate. Additionally, the system has the ability to increase or decrease the volume and pressure of injection. This technology
is unique to MIT’s MED-JET MBX Injector. The system is designed to inject up to 600 individuals an hour.
The
costs resulting from needle stick injuries vary widely. Accidental needle sticks involving sterile needles involve relatively
little cost. Needle sticks with contaminated needles require investigation and follow-up. These are much more expensive. Investigation
typically includes identifying the source of contamination, testing the source for blood-borne pathogens and repeatedly testing
the needle stick victim for infection over an extended period. Some healthcare providers are requiring additional measures, including
treating all needle stick injuries as contaminated unless proven otherwise. The most important problem that most needle stick
victim will have is the stress during all these extended period not knowing what will happen to them day in day out and that sometime
could be over a six month period for them and their families and friends waiting for each and every test result until the end
of the process and sometime beyond.
Some
effort has been done to protect healthcare workers from needle stick injuries, many healthcare facilities worldwide are trying
to adopt more expensive alternative technologies, these technologies can help reduce accidental needle sticks, but they can’t
eliminate the risk, unless they use needle-free technologies.
Medical
International Technology Inc., objective is to ensure that our injectors become an indispensable and environmentally friendly
product for doctors, dentists, nurses, veterinarians, farmers and home users around the world.
MIT
is pleased to continue providing a safe and effective means to help prevent the spread of deadly diseases to both humans and animals
through the use of the Med-Jet®, Agro-Jet® and Avian-Jet needle-free injection systems.
Description
of our Products
Focusing
on existing salable product line:
Human
applications:
| ● | MED-JET
Model MIT-MBX.(Medical and Cosmetic dermatology) |
| ● | MED-JET
Model MIT-H-III.(Medical and Cosmetic dermatology and Mass vaccination) |
| ● | MED-JET
Model MIT-MESO-JET. (Medical and Cosmetic dermatology) |
| ● | MED-JET
Model MIT-H4. (Single and Mass vaccination, uses auto-disabling single shot disposable
cartridge to eliminate the possibility of both pre-injection contamination and post-injection
cross-contamination |
Animal
applications:
| ● | AGRO-JET
Model MIT-II (Small farm animal vaccination) |
| ● | AGRO-JET
Model MIT-III (Up to 50Kg animal vaccination) |
| ● | AGRO-JET
Model MIT-V(Pets clinic use vaccination) |
| ● | AGRO-JET
Model MIT-5D(Pets clinic usevaccination, uses auto-disabling single shot disposable cartridge
to eliminate the possibility of both pre-injection contamination and post-injection cross-contamination |
| ● | AGRO-JET
Model MIT-VI(live stock vaccination) |
| ● | AGRO-JET
Model MIT-X(live stock vaccination) |
| ● | AGRO-JET
Model MIT-NBM (Small farm animal vaccination) |
| ● | AVIAN-JET(Poultry
vaccination) |
| ● | MINI-JET
(day old chick vaccination) |
Medical
International Technology Inc. will focus its Marketing and sales on the salable products line in the Human and Animal applications
to their existing Distributors and Agents. The only new product that will be introduced in 2015 will be the MED-JET H4 and the
MINI-JET for day old chick vaccination.
MIT’s
patented technology has received approval in several countries worldwide. The Company expects that the new products will be no
exception.
The
Company will do a new attempt in 2016 to achieve the US FDA 510K certification taking in consideration the new regulations.
In
the coming two fiscal years 2015 and 2016, MIT intent is to focus primarily on the marketing and sales of its existing products
and the two new products namely MED-JET H4 for humans and the MINI-JET for day old chicks.
Market
Breakdown
Human
applications:
In
the next fiscal year 2015, the Company plans to expand its market for cosmetic dermatology, plastic surgery, and general practitioner
for single and mass injections. It will do so through the use of the Med-Jet models MIT MBX, the MESO-JET and MIT-H-III.
The Company will also introduce to few specific markets the new MED-JET H4 for single vaccine and other biologic injections.
Animal
applications:
In
the next fiscal year 2015, the Company plans to Market and sell its existing AGRO-JET line of products and its new MINI-JET for
day old chick vaccination.
Patents
and Trademarks
We have
obtained trademark registration in the United States on the use of AGRO-JET (Reg. No. 2,712,089) and MED-JET (Reg. No. 2,798,613).
We have
obtained trademark registration in Canada on the use of AGRO-JET (Reg. No. TMA 624,735) and MED-JET (Reg. No.TMA 624,737), and
MESO-JET (Reg. No.TMA 885,180).
We have
applied for a PCT Patent application in Europe, China, Taiwan, Japan, USA, and Canada for new patents.
Regulation
and Approvals
We
manufacture and sell products that may require various approvals by government agencies in the locals in which they are used.
These regulations or approvals vary greatly depending upon the way our products are used. We may not have the required approvals
for various applications of our products in those localities. We continue to seek approvals for various applications of our products
but the costs associated with achieving such approvals may exceed our available resources or be commercially impracticable.
We
have received full certification for our Quality Management System granted under the International Organization for Standardization's
ISO: 9001:2000. This includes Certification for the “Canadian Medical Device Conformity Assessment System” (CMDCAS),
for devices to be licensed by Health Canada. The company plans to aggressively market the MED-JET for human use for mass-inoculation.
The company feels that Canada and other world markets can benefit greatly from the MED-JET. By using the MED-JET, health officials
have an alternative delivery method that is safer and faster than the traditional needle. These certifications allow us to market
the Med-Jet Needle-Free injector for human use in all countries other than the United States, at this point. The Med-Jet injector
will be re submitted for FDA approval, which, if accepted, will allow us to sell the Med-Jet in the United States, making it a
truly worldwide system. The approval process for the U.S. FDA is expensive and may take an extended period of time.
We will target for 2016 the actual MED-JET products to receive approval from the FDA.
In
September 2014 we have initiated our Health Canada Certification for our Model Med-Jet H-4 that will target all vaccination clinics,
hospitals in many Countries; the Med-Jet H-4 can also be used in many other departments that have needs for biologic single injections.
Product
Development
Per
our previous fillings for FDA approval for our needle-free injector, the MED-JET is designed specifically for human mass inoculations.
The MED-JET is capable of delivering many types of medications such as vaccines, insulin and other types of injectables. Its low-pressure
technology offers an advantage to alternative high pressure systems that can cause blowbacks and expose medical workers and patients
alike to microscopic traces of blood.
According
to the International Sharps Injury Prevention Society (http://www.isips.org), it has been estimated that one out of every seven
workers is accidentally struck by a contaminated sharp point each and every year. The Center for Disease Control (CDC: http://www.cdc.gov/niosh/2000-108.html#5)
estimates that there are 600,000 to 800,000 needle stick injuries per year in the U.S. alone, and many are not reported. More
than 20 types of infectious agents have been transmitted through needle sticks, including hepatitis B and C, tuberculosis, syphilis,
malaria, herpes, diphtheria, gonorrhea, typhus and Rocky Mountain spotted fever. The MED-JET will eliminate this risk to health
care professionals and create a safer workplace. Other advantages include its light weight (0.5 kg) and an excellent medication
absorption rate. Additionally, the system has the ability to increase or decrease the volume and pressure of injection. This technology
is unique to MIT’s MED-JET MBX Injector. The system is designed to inject up to 600 individuals an hour.
The
approval process can be expensive and may take an extended period of time. There can be no assurance that this system will receive
approval from the FDA or if approved gain broad acceptance by the medical community or individual patients.
During
the last quarter of 2011 we signed with an outside consultant to help MIT with the FDA approval process and to expedite the approval. This
work has been stopped temporarily and will restart during fiscal year 2016/2017.
On
December 15, 2005, we received full certification granted under the International Organization for Standardization, as well as
the Canadian Medical Device Conformity Assessment System for devices to be licensed by HEALTH CANADA. These certifications allow
MIT to currently market the Med-Jet Needle-Free Injector for human use in many countries other than the U.S. The Med-Jet injector
has been submitted for FDA approval which, if accepted, will allow MIT to sell the Med-Jet and Meso-Jet in the United States,
making it a truly worldwide system.
MIT's
Needle-Free Injection System, designed specifically to allow fast, accurate and safe injections, is rapidly moving toward establishing
itself as a valuable instrument in the fight against disease in both humans and animals. Spurred on by growing fears of a worldwide
epidemic that could match or even exceed the deadly flu pandemic of 1918 which killed millions of people, the MIT team is focusing
its efforts to make its Needle-Free Injection System available to the world.
Now
that MIT is able to sell its Med-Jet in many countries other than the U.S., it will restart during fiscal year 2016/2017 The first
of these will be for use of the Med-Jet for injecting anesthesia in a variety of situations. The second, and most significant
in light of the news coming out of Asia concerning the spread of Influenza A (H1N1) to humans, will be the Med-Jet-H III and H-4,
for mass vaccination in case of a pandemic, such as Avian Influenza, Polio, Tuberculosis, Malaria, HIV and the new Ebola virus
outbreak.
MIT
will increasingly promote its Agro-Jet and Avian-Jet needle-free injector designed specifically for poultry vaccination. Having
the same benefits as Med-Jet, Agro-Jet and Avian-Jet will become a valuable instrument in the fight against Avian Flu via its
ability to mass inoculate animals at over 1000 injections per hour.
Marketing
and Competition
The
traditional needle-syringe is currently the primary method for administering intradermal, subcutaneous and intramuscular injections.
For
the past 30 years, many inventors attempted to develop portable needle-free multiple shots injection for diabetic insulin injections
market, during the past 22 years inventors have developed single shot needle-free jet injection devices, in the two cases most
of them have developed high pressure injectors without taking in consideration many of the following points:
| 1. | Pressure
power and control |
| 2. | Pressure
control for different sites and skin |
| 3. | Control
of penetration depth |
| 4. | Control
and adjustment of injected volume |
| 5. | User
friendly mechanism to adjust pressure and volume |
| 6. | Cost
performance for manufacturing and reliability |
| 7. | User
friendly cleaning and sterilization |
During
the past 10 to 15 years many needle-free products has been developed and sold mainly for diabetic markets, some of these spring
loaded devices are making some inroad into the market place in many countries, these products could help create people awareness
towards needle-free technology as another possible non-invasive and less painful environmentally friendly than the standard hypodermic
needle/syringe, the fact that other needle-free products come on the market will also increase competition and some of the niche
market that MIT is also targeting.
We
can also see competition from various versions of new “safety syringe” that have been designed and marketed in different
versions to have a certain plastic guard surrounding the needle that can retracted or removed in order to give an injection, the
safety guard is designed to reduce or eliminate needle stick injuries while the safety syringe is in use and before the needle
has been covered, the safety syringe still poses a big risk of injury to the users. Other type of safety syringes require manipulation
after injection and pose a bigger risk of needle stick injury during manipulation.
We
believe that our primary competition is the traditional, disposable needle-syringe and the safety syringe. Leading suppliers
of needle-syringes and safety syringes include: Becton-Dickinson & Co., Sherwood Medical Co., a subsidiary of Tyco
International, and Terumo Corp. of Japan and the new Chinese manufacturer. Usually needle-syringes manufacturers compete
primarily on price, which generally ranges from approximately $0.15 to $0.45 per unit, manufacturers of safety syringes
compete on price, features and quality, they are generally priced in a range of $0.45 to $1.45 per unit for volume
sales.
Employees
Currently,
the company has three employees and four consultants. As our operations are expanded additional employees and consultants will
be required.
Item
1A. Risk Factors
The
following risk factors should be considered in the evaluation of our business. Our business financial condition and results of
operations could be materially adversely affected by any of these risks. Please note that additional risks not presently known
to us or that we currently deem immaterial may also impair our business and operations.
| ● | We
need to increase sales. |
| ● | We
need to raise Capital in 2015 to continue operations. |
| ● | Sufficient
Capital may not be available. |
| ● | If
available, may be subject to important conditions. |
| ● | The
unavailability of Capital could adversely affect our business and cause us to cease operations. |
We
continue to monitor our operation and cash flow daily as we have always done, we can also take drastic measures to reduce our
expenditure rate. However, if we do not increase our sales, enter into one or more Agent, Distribution agreements increase sales,
we may need to do one or more of the following to provide additional resources during 2015:
●
Secure additional debt financing.
●
Secure additional equity financing.
●
Secure a strategic partner.
Our
common stock is listed on the Over-the-Counter Bulletin Board, which may impair the price at which our common stock trades, and
the liquidity of the market for our common stock and our ability to obtain additional funding. The Over-the-Counter Bulletin Board
is an electronic quotation service maintained by the Financial Industry Regulatory Authority. Our stock, like most stock listed
on this service, has very limited trading volume. As a consequence, the ability of a stockholder to sell our common stock, the
price obtainable for our common stock and our ability to obtain additional funding may be materially impaired.
Item
1B. Unresolved Staff Comments
We are
not required to provide this information as we are a smaller reporting company.
Item
2. Properties
The
Company leases its office and warehouse space under an operating lease that expires on December 31, 2014. The company
has negotiated an extension for one more year until December 31, 2015 at the same rent amount and conditions of 2014. The
lease calls for a monthly rent of $4,248 (CND) Rent expense for the years ended September 30, 2014 and 2013 was approximately
$47,600 and $51,000, respectively.
Item
3. Legal Proceedings
We
are currently not involved in any litigation that we believe could have a material adverse effect on our financial condition or
results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government
agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our company or any of our
subsidiaries, threatened against or affecting our company, our common stock, any of our subsidiaries or of our companies or our
subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse
effect.
Item
4. Mine Safety Disclosures
Not
applicable.
PART
II
Item
5. Market for Common Equity and Related Stockholder Matters
Market
Information
Our
common stock is currently listed on the OTCBB under the symbol “MDLH.” As of September 30, 2014, 83,804,627
shares of our common stock were issued and outstanding.
Of
the 83,804,627 shares of our common stock issued and outstanding, 64,927,074 of such shares are restricted shares.
None of these restricted shares are eligible for resale absent registration or an exemption from registration.
Price
Range of Common Stock
The
following table sets forth the high and low trade information for our common stock for each quarter for the previous two years.
The prices reflect inter-dealer quotations, do not include retail mark-ups, markdowns or commissions and do not necessarily reflect
actual transactions.
| | |
High | | |
Low | |
| Fiscal Year 2013 | |
| | | |
| | |
| First quarter ended December 31, 2012 | |
$ | .10 | | |
$ | .03 | |
| Second quarter ended March 31, 2013 | |
$ | .10 | | |
$ | 03 | |
| Third quarter ended June 30, 2013 | |
$ | .10 | | |
$ | .03 | |
| Fourth quarter ended September 30, 2013 | |
$ | .10 | | |
$ | .03 | |
| | |
| | | |
| | |
Fiscal Year 2014 | |
| | | |
| | |
| First quarter ended December 31, 2013 | |
$ | .05 | | |
$ | .02 | |
| Second quarter ended March 31, 2014 | |
$ | .17 | | |
$ | .02 | |
| Third quarter ended June 30, 2014 | |
$ | .05 | | |
$ | .02 | |
| Fourth quarter ended September 30, 2014 | |
$ | .03 | | |
$ | .02 | |
Holders
As
of the date of this Report there were approximately 93 holders of record of our common stock. This number does not include shares
held by brokerage clearing houses, depositories or others in unregistered form.
Dividend
Policy
We
have not paid a cash dividend on its common stock in the past 12 months. The company does not anticipate paying any cash dividends
on its common stock in the next 12-month period. Management anticipates that earnings, if any, will be retained to
fund the company's working capital needs and the expansion of its business. The payment of any dividends is at the
discretion of the Board of Directors.
Securities
Authorized for Issuance under Equity Compensation Plans
The following
table sets forth certain information as of the date hereof, with respect to compensation plans under which our equity securities
are authorized for issuance:
| |
(a) |
|
(b) |
|
(c) |
| |
Number
of securities
to
be issued upon
exercise
of
outstanding
options,
warrants
and rights |
|
Weighted-average
exercise
price
of
outstanding
options,
warrants
and rights |
|
Number
of securities remaining
available
for future issuance
under
equity compensation plans
(excluding
securities
reflected
in column (a)) |
| |
|
|
|
|
|
| Equity compensation |
None |
|
|
|
|
| Plans approved by |
|
|
|
|
|
| Security holders |
|
|
|
|
|
| |
|
|
|
|
|
| Equity compensation |
None |
|
|
|
|
| Plans not approved |
|
|
|
|
|
| By security
holders |
|
|
|
|
|
| Total |
|
|
|
|
|
Item
6. Selected Financial Data
We
are not required to provide the information required by this Item because we are a smaller reporting company.
Item
7. Management's Discussion and Analysis of Financial Condition and Results of Operations
CAUTIONARY
STATEMENT RELATED TO FORWARD LOOKING STATEMENTS
This
Annual Report on Form 10-K (this “Report”) contains “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Exchange Act.
Forward-looking statements discuss matters that are not historical facts. Because they discuss future events or conditions, forward-looking
statements may include words such as “anticipate,” “believe,” “estimate,” “intend,”
“could,” “should,” “would,” “may,” “seek,” “plan,” “might,”
“will,” “expect,” “predict,” “project,” “forecast,” “potential,”
“continue” negatives thereof or similar expressions. These forward-looking statements are found at various places
throughout this Report and include information concerning possible or assumed future results of our operations; business strategies;
future cash flows; financing plans; plans and objectives of management; any other statements regarding future operations, future
cash needs, business plans and future financial results, and any other statements that are not historical facts.
From
time to time, forward-looking statements also are included in our other periodic reports on Forms 10-Q and 8-K, in our press releases,
in our presentations, on our website and in other materials released to the public. Any or all of the forward-looking
statements included in this Report and in any other reports or public statements made by us are not guarantees of future performance
and may turn out to be inaccurate. These forward-looking statements represent our intentions, plans, expectations, assumptions
and beliefs about future events and are subject to risks, uncertainties and other factors. Many of those factors are
outside of our control and could cause actual results to differ materially from the results expressed or implied by those forward-looking
statements. In light of these risks, uncertainties and assumptions, the events described in the forward-looking statements might
not occur or might occur to a different extent or at a different time than we have described. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date of this Report. All subsequent written and oral
forward-looking statements concerning other matters addressed in this Report and attributable to us or any person acting on our
behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this Report.
Except
to the extent required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result
of new information, future events, a change in events, conditions, circumstances or assumptions underlying such statements, or
otherwise.
The
following discussion should be read in conjunction with the Consolidated Financial Statements and Notes thereto appearing elsewhere
in this Form 10-K. The following discussion contains forward-looking statements within the meaning of Section 27A of the Securities
Act of 1933 and Section 21E of the Securities Exchange Act of 1934 relating to future events or our future performance. Actual
results may materially differ from those projected in the forward-looking statements as a result of certain risks and uncertainties
set forth in this prospectus. Although management believes that the assumptions made and expectations reflected in the forward-looking
statements are reasonable, there is no assurance that the underlying assumptions will, in fact, prove to be correct or that actual
results will not be different from expectations expressed in this report.
Overview
Medical
International Technology, Inc. (“MIT” or the “Company”) was incorporated in the State of Colorado on July
19, 1999.Our wholly-owned subsidiary, Medical International Technologies (MIT Canada). Inc., a Canadian company was acquired in
June 2002 and is based in Montreal. We specialize in production, marketing and the sale of needle-free jet injector products designed
for humans and animals applications, for single and mass injections. Needle-free jet injector technology and products provide
advantages over traditional needle injection techniques and products, including; efficiency, handling security, biological waste
elimination, and patient stress reduction.
The
Company concentrates its activities in the medical and Para-medical sectors, in particular, in the field of medical devices. Our
strategy is to build a market for its different products and establish strategic alliances with different pharmaceutical companies,
medical devices distributors and manufacturers to ensure good distribution channels for its products.
The
benefits of needle-free injection compared to needle injection, in particular with respect to the features of our products, can
be summarized as follows:
| 1. | Less
tissue damage and less painful; |
| 2. | Simple,
fast and effective; |
| 3. | Precise,
reliable and safe; |
| 4. | Good
absorption of liquids; |
| 5. | Prevents
stress from traditional needle syringes and infections from contaminated needles; |
| 6. | Friendly
to the environment (no biological waste); |
| 7. | Affordable
and economical; and |
| 8. | Efficient
use of medication used. |
The
Company’s major source of revenues is from sales of its Needle-Free products for Human and Animal application. The Company
has maintained operations from these revenues and through equity and debt financing. The company has been dependent on advances
from related parties to maintain operations. There are no agreements, assurances or commitments to continue providing these advances.
Products are currently produced, assembled and shipped from our facility. Component manufacturing is subcontracted to various
suppliers and machine shops.
MIT’slong-term
goal is to become one of the leading suppliers of needle-free injection systems to the health industry worldwide. We have been
focusing our business development efforts on new and existing companies to distribute our unique needle-free products in human
and animal applications in the international market. We have collaborated and are still collaborating with different pharmaceutical
corporations in China and other countries that could lead to long-term agreements. We are actively pursuing additional opportunities
in the global market. However, finalizing long term agreements is a long process that could take even longer to negotiate given
the current difficult global economic conditions.
On
May 6, 2009, we entered into a joint venture agreement (the “Joint Venture Agreement”) with Jiangsu Hualan Biotechnology
Ltd. (China) (“Jiangsu Hualan”). Pursuant to the Joint Venture Agreement, the parties established a joint venture
company, Jiangsu Hualan MIT Medical Technology (MIT China) Ltd. (“MIT China”), focusing on research, production and
sales of medical equipment, import and export of medical equipment and components products, especially Needle-Free Jet Injector
products.
The
creation of MIT China in June of 2009 can give MIT a unique advantage to expand its production operations and increase its sales
and profits in the worldwide needle-free injector market. Furthermore, MIT China venture could help MIT supply large production
volumes in less time, which could attract large medical and pharmaceutical partners.
The
introduction of our Agro-Jet needle-free injector for animal application did not progress as well as believed. Our veterinary
staff has successfully trained our distributors in various regions, and the distributors didn’t market the product as per
our understanding. The Company has re-discussed with our distributors and we now expect that these efforts will result in sales
growth in fiscal year 2015.
During
the third quarter of fiscal year 2011, MIT China purchased 151,000 sq. ft. of land and began construction of our first building
in Taizhou (China Medical City). This first building of 40,000 sq. ft. when finalized will be used for the production of injectors
for the Chinese market only.
Work
in progress at MIT China for the construction of its 40,000 sq. ft. building, the first stage (the offices) has been completed,
and our first move of all our employees to Taizhou was conducted in the beginning of August 2012. The other part of the construction
was scheduled to be completed in the first quarter of 2013/2014 fiscal year, even though our managements and engineers where working
hard to plan the purchasing of the equipment and tools necessary for the assembly and production of some of our Agro-Jet and Med-Jet
products, they were not able to finalize on time. This production facility when finalized should be able to supply a large number
of injectors and disposables to the Chinese market; we expect the production facility to be ready by the first quarter of 2016.
On
November 2011 and per the discussions with our Chinese general manager, Mr. Ethan Sun, our Joint Venture partner, our plan of
sales and expansion into the Chinese market is progressing and MIT China needed more money to expand its operations therefore
MIT China agreed to sell and sold 9% of their joint venture for an investment of 18,000,000 RMB (US$3,000,000). This capital investment
received has reduced the two original partners Jiangsu Jiabo Investment LTD percentage to 46.41% from 51% and MIT Canada to 44.59%
from its 49% and Taizhou Amazon Investment Center, our new partner received 9% ownership in MIT China venture.
In
2012 we have supplied to CDC (Centre of Disease Control) vaccination clinic in China with one Med-Jet model MIT H-III, and requested
an MIT China nurse to be present at the clinic at all times for training, supervision of the proper usage and procedures of our
Med-Jet for vaccination., the results were very good and we have expected more uses of our Med-Jet H-III from many of the CDC
clinics and hospitals across China in fiscal year 2013 which didn’t happen so far, because of the price index that is taking
longtime to receive, we expect to have the price index issue resolved for 2016.
In
2012 we were proceeding positively with our Chinese SFDA for our new Med-Jet model H-4, and in 2013 we added the new product called
DART that uses similar anti-contaminant single use disposable cartridge and we were expecting our certification in the second
quarter of 2013/2014 fiscal year, unfortunately we couldn’t achieve our objective, it is now expected in the Second or third
quarter of 2016.
Our
Model Med-Jet H-4 will target all vaccination clinics, hospitals, all CDC Centers and many other departments that have needs for
single use disposable cartridge biologic injections.
Also
as per the Model Med-Jet H-4, the Model Med-Jet DART, was developed mainly for intra-dermal vaccination and more specifically
for the Polio vaccination in collaboration with a major Chinese pharmaceutical company, the animal protocol trials took place
in China during 2013 and it is now completed, we were expecting the final results and report during the second quarter of 2013/2014.
If the results will be positive and in favor of MIT Canada, we will then be invited to participate in the second and final trial
that will implicate human vaccine trials and will be expected to take place in China and towards the end of year 2014, thereafter
we should expect a major supply agreement to be concluded with the same Chinese Pharmaceutical Company and hopefully many others.
Unfortunately we didn’t receive so far the final results from the Animal study; we are still expecting the final report
to be issued officially in the Second or third quarter of 2016.
Every
year we face with new challenges, in 2014 these challenges were significant and only added to the hurdles we face in trying to
achieve and realize positive results with the above business strategies we have outlined. During 2014, there were some significant
distribution potential agreements, which did not materialize as expected even though there was strong interest in our products.
In addition some of the Countries, namely Russia, South Korea Mexico to name few had very bad economical situations in their respective
Countries, Our Chinese partners had many delays in obtaining different certifications and price index in the province they had
applied resulting in loss of sale and orders to MIT Canada, furthermore this situation persisted during the entire year impacted
both revenue and cash flow throughout the year, at the same time we have continued to focus on carefully managing our fixed operating
expenses
While
revenues in 2014 were lower than in 2013, we have taken actions related to both revenue and cash management in an attempt to improve
our results. Such actions has included focusing by Mr. Karim Menassa on increasing sales of our devices to our existing and active
Distributors and Agents, giving them full support in their endeavour to sell our products. We are also exploring new options in
regards to new possible Joint Ventures in Marketing, sales and training centers in collaboration with Distributors and Doctors
/ Nurses.
Our
2014 revenues and results of operations same as previous years have fluctuated and can be expected to continue to fluctuate significantly
from quarter to quarter and from year to year. Various factors may affect quarterly and yearly operating results, including the
following:
| ● | Worldwide
economic situation since we are Marketing and selling internationally. |
| ● | The
length of time to close product sales, especially with new Distributors. |
| ● | Customer
budget cycles. |
| ● | Certification
time line in different markets. |
| ● | Price
index especially in China market. |
| ● | New
product introductions. |
| ● | New
attempt to achieve the US FDA 510K certification taking in consideration the new regulations. |
| ● | Other
unforeseen negative situation worldwide. |
Medical
International Technology Inc.’s, objective is to ensure that our injectors become an indispensable and environmentally friendly
product for doctors, dentists, nurses, veterinarians, farmers and home users around the world.
The
Company is pleased to continue providing a safe and effective means to help prevent the spread of deadly diseases to both humans
and animals through the use of the Med-Jet®, Agro-Jet® and Avian-Jet needle-free injection systems.
Management
Plan of Operations
Medical
International Technology's intends to concentrate its activities in the medical and veterinary sectors, in particular, in the
field of equipment and instrumentation. The company's strategy is to build good, reliable and cost effective products, seek and
establish strategic alliances with different pharmaceutical companies and manufacturers to ensure good distribution channels for
its products.
MIT
promotes and sells products in over 30 countries including the United States of America. MIT is exerting every effort and using
its resources to promote its products and to open markets for its technology. As we continue to market our products, we hope to
gain broader acceptance of the needle-free injection technology. MIT is continually researching and developing its products to
the market needs.
We
will continue to seek additional funding to expand operations and develop sales revenue to a volume sufficient to sustain operations
and increase shareholders value.
Results
of Operations
Comparison
for the year ended September 30, 2014 to the year ended September 30, 2013
The
following table presents the statement of operations for the year ended September 30, 2014 as compared to the year ended
September 30, 2013. The discussion following the table is based on these results.
| | |
Years Ended September 30, | |
| | |
2014 | | |
2013 | |
| | |
| | |
| |
| Revenues | |
$ | 425,487 | | |
$ | 846,782 | |
| Cost of sales | |
| 88,439 | | |
| 305,490 | |
| Gross profit | |
| 337,048 | | |
| 541,292 | |
| | |
| | | |
| | |
| Operating expenses | |
| | | |
| | |
| | |
| | | |
| | |
| Selling, general and administrative expenses | |
| 405,275 | | |
| 471,780 | |
| Total operating expenses | |
| 405,275 | | |
| 471,780 | |
| Operating income (loss) | |
| (68,227 | ) | |
| 69,512 | |
| | |
| | | |
| | |
| Other: | |
| | | |
| | |
| | |
| | | |
| | |
| Equity earnings (loss) on MIT China Joint Venture Other income | |
| - | | |
| (146,343 | ) |
| | |
| | | |
| | |
| Non-refundable Distribution Rights Deposit, | |
| - | | |
| 1,072,500 | |
| Interest expense | |
| (11,737 | ) | |
| (12,904 | ) |
| Total other income (expense) | |
| (11,737 | ) | |
| 913,253 | |
| | |
| | | |
| | |
| Net income (loss) | |
$ | (79,964 | ) | |
$ | 982,765 | |
Revenues
The
Company’s consolidated revenues decreased by $421,295 or 50% to $425,487 during the fiscal year ending September
30, 2014. This reduction of revenues was primarily due to the market situation in general.
Our
Russian distributor started the year purchasing their first order. The order was paid for and shipped. Thereafter, the Ukraine
war started and the distributor had to put a hold on all scheduled sales pending the situation. No other product has been sold
to our Russian distributor.
Other
economic and private situations happened in other countries. South Korea and Mexico, to name few, had very bad economic
situations in their respective countries. Our Chinese partners had many delays in obtaining different certifications and
price index in the province they had applied resulting in loss of sale and orders to MIT Canada, furthermore this situation
persisted during the entire year impacting both revenue and cash flow throughout the year. At the same time, we have
continued to focus on carefully managing our fixed operating expenses making our 2014 year sales very difficult and
stressful.
We
continue to believe that our marketing policy and strategy this year and in the future is to continue the search for distributors
in different markets with the following criteria in place to become an MIT distributor:
| ● | Financial
stability. |
| ● | Strong
management. |
| ● | Strong
marketing and sales team. |
| ● | Understanding
MIT technologies and have a medical team. |
| ● | A
strong technical support team. |
We
continue to believe the importance of providing adequate support to our distributors as we expand our network in order to increases
sales. The Company could not establish an internal marketing representative to provide support for its distributors for financial
reasons; the Management and the Operation Director has regularly assist our network of distributors in their marketing activities
by training the distributor’s sales representatives via video-conferences, providing support for after-sales service, making
regular visits, be present at certain important national and international exhibitions or presentations to potential buyers. In
addition, MIT’s main priority has and always will be its customer satisfaction.
MIT’s
marketing and Sales strategies in the medium and long term are the following:
| ● | Conduct
more trials with renowned doctors to respond to new needs in the medical community. |
| ● | Hire
and train qualified marketing representatives with international experiences. |
| ● | Searching
for new dynamic and experience Distributors worldwide. |
Cost
of Sales
The
cost of sales decreased by $217,051 in 2014. This decrease was directly related to our reduced sales in 2014, and our ability
to monitor our operation and cash flow daily as we have always done.
Gross
Profit
The
gross profit decreased by 38% for the year ending September 30, 2014. This decrease is due primarily as some of our distributors
did not perform as per our expectations, mainly because of their economic situations, resulting in a decrease of sales in our
consolidated revenues of $425,487 or 50 % in comparison to the year end 2013 of $846,782.
Our
Russian distributor who has started the year purchasing the first order, the order was paid for and shipped, thereafter the Ukraine
war started and the distributor had to put a hold on all scheduled sales pending the situations far not a single product has been
sold to our Russian distributor.
Other
economic and private situations happened in other countries. South Korea and Mexico, to name few, had very bad economic
situations in their respective countries. Our Chinese partners had many delays in obtaining different certifications and
price index in the province they had applied resulting in loss of sale and orders to MIT Canada, furthermore this situation
persisted during the entire year impacting both revenue and cash flow throughout the year. At the same time, we have
continued to focus on carefully managing our fixed operating expenses making our 2014 year sales very difficult and
stressful.
Operating
Expenses
We
have managed to reduce our cost in our operations in general and were directly related to our reduced sales in 2014, and our ability
to monitor our operation and cash flow daily including; selling, general and administrative expenses and the results was a decrease
by $66,505 to $405,275 during the fiscal year ended September 30, 2014.
Liquidity
and Capital Resources
During
the fiscal year ending September 30, 2014 the Company’s cash position increased by $32,747. Net cash provided by operating
activities was $63,978, resulting primarily from accounts receivables. Net cash provided by financing activities was
$32,148, resulting primarily from repayment of bank loans of $56,028 and the increase of amounts due at related parties of $80,000. Net
cash used by investing activities was $26,774 resulting primarily from the acquisition of patents. The effect
of exchange rates on cash during fiscal 2014 resulted in decrease in cash value of $36,605.
During
the fiscal year ending September 30, 2013 the Company’s cash position decreased by $302,477. Net cash used by operating
activities was $160,519, resulting primarily from changes in working capital accounts as well as the charge-off of the distribution
rights agreement. Net cash used by financing activities was $95,390, resulting primarily from repayment of bank loans
of $56,930 and the bank line of $38,460. Net cash used by investing activities was $86,207 resulting primarily from
the acquisition of tooling and machinery of $ 37,920 and acquisition of patents of $48,287. The effect of
exchange rates on cash during fiscal 2013 resulted in an increase in cash value of $39,639.
The
Company has reported accumulated losses since inception of $12,269,363, which raises substantial doubt about the Company’s
ability to continue as a going concern. The continuation of the Company is dependent upon the continuing financial support of
creditors and stockholders and upon obtaining the capital requirements for the continuing operations of the Company. Management
believes actions planned and presently being taken provides the opportunity for the Company to continue as a going concern.
During
the year ended September 30, 2014, no common stock was issued.
The
Company expects that revenues from existing and developing sales may not meet its liquidity requirements for the next 12-month
period at its current level of operations. The company has been dependent on advances from related parties to maintain operations.
There are no agreements, assurances or commitments to continue providing these advances. The company continues to rely on management
to develop the business and work to develop sales. Management has and may continue to supplement cash flows from sales with additional
equity and debt financing. Substantially, expanded operations are expected to require additional capital, either from a future
offering of equity or the company pursuing other methods of financing, as appropriate.
Off-Balance
Sheet Arrangements
We
do not have any off-balance sheet arrangements, financings, or other relationships with unconsolidated entities or other persons,
also known as “special purpose entities” (SPEs).
Critical
Accounting Policies
The
accompanying discussion and analysis of our financial condition and results of operations are based upon our financial statements,
which have been prepared in accordance with accounting principles generally accepted in the United States of America (“US
GAAP”). The preparation of these financial statements requires us to make estimates and judgments that affect the reported
amounts of assets, liabilities, revenues, and expenses, and related disclosure of contingent assets and liabilities. These estimates
form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other
sources. We base our estimates and judgments on historical experience and all available information. However, future events are
subject to change, and the best estimates and judgments routinely require adjustment. US GAAP requires us to make estimates and
judgments in several areas, including those related to recording various accruals, income taxes, the useful lives of long-lived
assets, such as property and equipment and intangible assets, and potential losses from contingencies and litigation. We believe
the policies discussed below are the most critical to our financial statements because they are affected significantly by management’s
judgments, assumptions and estimates.
Foreign
Currency Translations
The
Company operates out of its offices in Montreal, Canada and maintains its books and records in Canadian Dollars. The financial
statements herein have been converted into U.S. Dollars. Balance sheet accounts have been translated at exchange rates in effect
at the end of the year. Income statement accounts have been translated at average exchange rates for the year.
Translation gains and losses are included as a separate component of stockholders’ equity.
New
Accounting Pronouncements
The
Company does not expect recently issued accounting standards or interpretations to have a material impact on the Company’s
financial position, results of operations, cash flows or financial statement disclosures.
Item
7A. Quantitative and Qualitative Disclosures about Market Risk
We
are not required to provide the information required by this Item because we are a smaller reporting company.
Item
8. Financial Statements and Supplementary Data
Medical
International Technology, Inc.
Financial
Statements
Contents
Report
of Independent Registered Public Accounting Firm
To
The Board of Directors and Stockholders of
Medical
International Technology, Inc.
We
have audited the accompanying consolidated balance sheet of Medical International Technology, Inc. and subsidiaries as of September
30, 2014, and the related consolidated statements of operations, comprehensive income (loss), stockholders’ equity (deficit),
and cash flows for the year then ended. These consolidated financial statements are the responsibility of the Company’s
management. Our responsibility is to express an opinion on these consolidated financial statements based on our audit.
We
conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards
require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements
are free of material misstatement. The Company has determined that it is not required to have, nor were we engaged to perform,
an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial
reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing
an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such
opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements,
assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial
statement presentation. We believe that our audit provides a reasonable basis for our opinion.
In
our opinion, the 2014 consolidated financial statements referred to above present fairly, in all material respects, the financial
position of Medical International Technology, Inc. and subsidiaries as of September 30, 2014, and the results of its operations
and its cash flows for the year then ended in conformity with accounting principles generally accepted in the United States of
America.
The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed
in Note 1 to the financial statements, the Company has suffered recurring losses from operations. Those conditions raise substantial
doubt about its ability to continue as a going concern. Management’s plans regarding those matters are also described in
Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
LBB &
Associates Ltd., LLP
November
17, 2015
Report
of Independent Registered Public Accounting Firm
To
The Board of Directors and Stockholders of
Medical
International Technology, Inc.
We
have audited the accompanying consolidated balance sheet of Medical International Technology, Inc. and subsidiaries as of September
30, 2013, and the related consolidated statements of operations, comprehensive income (loss), stockholders’ equity (deficit),
and cash flows for the year then ended. These financial statements are the responsibility of the Company’s management. Our
responsibility is to express an opinion on these financial statements based on our audit.
We
conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards
require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material
misstatement. The Company has determined that it is not required to have, nor were we engaged to perform, an audit of its internal
control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for
designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the
effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit
also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing
the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement
presentation. We believe that our audit provides a reasonable basis for our opinion.
In
our opinion, the 2013 consolidated financial statements referred to above present fairly, in all material respects, the financial
position of Medical International Technology, Inc. and subsidiaries as of September 30, 2013, and the results of its operations
and its cash flows for the year then ended in conformity with accounting principles generally accepted in the United States of
America.
The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed
in Note 1 to the financial statements, the Company has suffered recurring losses from operations. Those conditions raise substantial
doubt about its ability to continue as a going concern. Management’s plans regarding those matters are also described in
Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
/s/
PS Stephenson & Co., P.C.
Wharton,
Texas
December
20, 2013
MEDICAL
INTERNATIONAL TECHNOLOGY
CONSOLIDATED
BALANCE SHEETS
| | |
September 30, | |
| | |
2014 | | |
2013 | |
| | |
| | |
| |
| Assets | |
| | |
| |
| Current assets | |
| |
| Cash and cash equivalents | |
$ | 33,767 | | |
$ | 1,020 | |
| Accounts receivable, net | |
| 1,461 | | |
| 66,209 | |
| Inventories | |
| 326,348 | | |
| 293,693 | |
| | |
| | | |
| | |
| Prepaid expenses | |
| 4,965 | | |
| 33,730 | |
| Total current assets | |
| 366,541 | | |
| 394,652 | |
| Property and Equipment | |
| | | |
| | |
| Tooling and machinery | |
| 654,976 | | |
| 720,594 | |
| Furniture and office equipment | |
| 153,157 | | |
| 144,312 | |
| Leasehold improvements | |
| 27,331 | | |
| 28,487 | |
| Total property and equipment | |
| 835,464 | | |
| 893,393 | |
| Less accumulated depreciation | |
| (623,452 | ) | |
| (707,496 | ) |
| Total property and equipment, net | |
| 212,012 | | |
| 185,897 | |
| | |
| | | |
| | |
| Patents (net of accumulated amortization of $40,625 and $20,855) | |
| 58,226 | | |
| 33,592 | |
| Investment in MIT China Joint Venture | |
| - | | |
| - | |
| Total assets | |
$ | 636,779 | | |
$ | 614,141 | |
| | |
| | | |
| | |
| Liabilities and Stockholder's Equity (Deficit) | |
| | | |
| | |
| | |
| | | |
| | |
| Current liabilities | |
| | | |
| | |
| Line of credit | |
$ | 71,376 | | |
$ | 63,200 | |
| | |
| | | |
| - | |
| Accounts payable and accrued expenses | |
| 123,931 | | |
| 121,944 | |
| Advance from related party | |
| 50,000 | | |
| - | |
| Current portion of long term debt | |
| 44,222 | | |
| 51,442 | |
| Total current liabilities | |
| 289,529 | | |
| 236,586 | |
| Long-Term Debt | |
| 42,798 | | |
| 91,606 | |
| Notes to related parties | |
| 30,000 | | |
| - | |
| Total liabilities | |
| 362,327 | | |
| 328,192 | |
| Commitments | |
| | | |
| | |
| Stockholder's Equity (Deficit) | |
| | | |
| | |
| Preferred stock, $.0001 par value; 3,000,000 shares authorized; | |
| | | |
| | |
| No issued and outstanding shares. | |
| - | | |
| - | |
| Common stock, $.0001 par value; 100,000,000 shares authorized; | |
| | | |
| | |
| 83,804,627 issued and outstanding | |
| 7,979 | | |
| 7,979 | |
| Additional paid-in capital | |
| 12,867,476 | | |
| 12,867,476 | |
| Accumulated deficit | |
| (12,269,363 | ) | |
| (12,189,399 | ) |
| Other comprehensive income (loss) | |
| (331,640 | ) | |
| (400,107 | ) |
| Total Stockholder's Equity (Deficit) | |
| 274,452 | | |
| 285,949 | |
| | |
| | | |
| | |
| Total Liabilities and Stockholder's Equity (Deficit) | |
$ | 636,779 | | |
$ | 614,141 | |
The
accompanying notes are an integral part of these consolidated financial statements.
MEDICAL
INTERNATIONAL TECHNOLOGY
CONSOLIDATED
STATEMENTS OF OPERATIONS
| | |
Years Ended September 30, | |
| | |
2014 | | |
2013 | |
| | |
| | |
| |
| Revenues | |
$ | 425,487 | | |
$ | 846,782 | |
| Cost of sales | |
| 88,439 | | |
| 305,490 | |
| Gross profit | |
| 337,048 | | |
| 541,292 | |
| | |
| | | |
| | |
| Operating expenses | |
| | | |
| | |
| Selling, general and administrative expenses | |
| 405,275 | | |
| 471,780 | |
| Total operating expenses | |
| 405,275 | | |
| 471,780 | |
| | |
| | | |
| | |
| Operating income (loss) | |
| (68,227 | ) | |
| 69,512 | |
| | |
| | | |
| | |
| Other income (loss) | |
| | | |
| | |
| Equity earnings (loss) on MIT China Joint Venture | |
| - | | |
| (146,343 | ) |
| | |
| | | |
| | |
| Non-refundable Distribution Rights Deposit | |
| - | | |
| 1,072,500 | |
| | |
| | | |
| | |
| Interest expense | |
| (11,737 | ) | |
| (12,904 | ) |
| Total other income (expense) | |
| (11,737 | ) | |
| 913,253 | |
| | |
| | | |
| | |
| Net Income ( loss) | |
$ | (79,964 | ) | |
$ | 982,765 | |
| | |
| | | |
| | |
| Net Income ( loss) per common share | |
$ | (0.00 | ) | |
$ | 0.01 | |
| Weighted average common shares outstanding - basic and diluted | |
| 83,804,627 | | |
| 83,804,627 | |
The
accompanying notes are an integral part of these consolidated financial statements.
MEDICAL
INTERNATIONAL TECHNOLOGY
CONSOLIDATED
STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
| | |
Years Ended September 30, | |
| | |
2014 | | |
2013 | |
| | |
| | |
| |
| Net income (loss) | |
$ | (79,964 | ) | |
$ | 982,765 | |
| Other comprehensive income (loss) | |
| | | |
| | |
| Foreign currency translation adjustment | |
| 68,467 | | |
| 12,252 | |
| Comprehensive income (loss) | |
$ | (11,497 | ) | |
$ | 995,017 | |
The
accompanying notes are an integral part of these consolidated financial statements.
MEDICAL
INTERNATIONAL TECHNOLOGY
CONSOLIDATED
STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)
| | |
| | |
| | |
Additional | | |
| |
| | |
Common Stock | | |
Paid-in | | |
Accumulated | |
| | |
Shares | | |
Amount | | |
Capital | | |
Deficit | |
| | |
| | |
| | |
| | |
| |
| Balance - September 30, 2012 | |
| 83,804,627 | | |
$ | 7,979 | | |
$ | 12,867,476 | | |
$ | (13,172,164 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Net income for the year ended September 30, 2013 | |
| | | |
| | | |
| | | |
| 982,765 | |
| | |
| | | |
| | | |
| | | |
| | |
| Balance - September 30, 2013 | |
| 83,804,627 | | |
$ | 7,979 | | |
$ | 12,867,476 | | |
$ | (12,189,399 | ) |
| Net(loss) for the year ended September 30, 2014 | |
| | | |
| | | |
| | | |
| (79,964 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Balance - September 30, 2014 | |
| 83,804,627 | | |
$ | 7,979 | | |
$ | 12,867,476 | | |
$ | (12,269,363 | ) |
The
accompanying notes are an integral part of these consolidated financial statements.
MEDICAL
INTERNATIONAL TECHNOLOGY
CONSOLIDATED
STATEMENTS OF CASH FLOWS
| | |
Years Ended September 30, | |
| | |
2014 | | |
2013 | |
| Cash flows from operating activities: | |
| | |
| |
| Net income (loss) | |
$ | (79,964 | ) | |
$ | 982,765 | |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | |
| | | |
| | |
| Equity loss from MIT China Joint Venture | |
| - | | |
| 146,343 | |
| Depreciation and amortization expense | |
| 81,097 | | |
| 135,431 | |
| Changes in: | |
| | | |
| | |
| Accounts receivable | |
| 64,748 | | |
| (10,142 | ) |
| Inventories | |
| (32,655 | ) | |
| 22,748 | |
| Prepaid expenses | |
| 28,765 | | |
| (13,529 | ) |
| Accounts payable and accrued liabilities | |
| 1,987 | | |
| (38,229 | ) |
| Non-refundable Distribution Rights Deposit | |
| - | | |
| (1,385,906 | ) |
| Net cash used by operating activities | |
| 63,978 | | |
| (160,519 | ) |
| | |
| | | |
| | |
| Cash flows from investing activities: | |
| | | |
| | |
| Acquisition of patents | |
| (26,774 | ) | |
| (48,287 | ) |
| Tooling and machinery | |
| - | | |
| (37,920 | ) |
| Net cash used by investing activities | |
| (26,774 | ) | |
| (86,207 | ) |
| | |
| | | |
| | |
| Cash flows from financing activities: | |
| | | |
| | |
| Line of credit | |
| 8,176 | | |
| (38,460 | ) |
| Bank loans | |
| (56,028 | ) | |
| (56,930 | ) |
| Proceeds from issuance of stock, net | |
| - | | |
| - | |
| Increase in amounts due to related parties | |
| 80,000 | | |
| - | |
| Net cash provided from financing activities | |
| 32,148 | | |
| (95,390 | ) |
| | |
| | | |
| | |
| Effect of exchange rates | |
| (36,605 | ) | |
| 39,639 | |
| | |
| | | |
| | |
| Increase (decrease) in cash | |
| 32,747 | | |
| (302,477 | ) |
| Cash, beginning of period | |
| 1,020 | | |
| 303,497 | |
| Cash, end of period | |
$ | 33,767 | | |
$ | 1,020 | |
| Supplemental disclosure of cash flow information: | |
| | | |
| | |
| Cash paid for interest | |
$ | 13,247 | | |
$ | 14,336 | |
| Cash paid for federal income taxes | |
$ | - | | |
$ | - | |
The
accompanying notes are an integral part of these consolidated financial statements.
MEDICAL
INTERNATIONAL TECHNOLOGY
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
YEARS
ENDED September 30, 2014 and 2013
Note 1 – Business Activities
and Related Risks
Medical
International Technology, Inc. (the "Company") was incorporated in Colorado on July 19, 1999, under the name, Posterally.com,
Inc. The Company filed an amendment to its articles of incorporation on September 24, 2002 changing its name to Medical International
Technology, Inc.
The
Company is in the business of manufacturing and marketing a needle free device for use in injecting medicine and supplements for
human and animal use.
Going
Concern:
Excluding
other income from the distribution rights agreement termination (Note 11), the Company has incurred net losses aggregating $169,299
during the two years ended September 30, 2014. In addition, the Company has accumulated losses of $12,269,363 since
inception and a stockholder’s equity of $274,452 at September 30, 2014. These factors, amongst others, raise substantial
doubt about the Company’s ability to continue as a going concern.
There
can be no assurance that sufficient funds required during the next year or thereafter will be generated from operations or that
funds will be available from external sources such as debt or equity financings or other potential sources. The lack of additional
capital resulting from the inability to generate cash flow from operations or to raise capital from external sources would force
the Company to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business.
Further, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they
will not have a significant dilutive effect on the Company’s existing stockholders.
The
accompanying financial statements do not include any adjustments related to the recoverability or classification of asset carrying
amounts or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern.
Note
2 – Summary of Significant Accounting Policies
Principles
of consolidation
The
accompanying financial statements include the accounts and transactions of Medical International Technology, Inc. and its wholly
owned subsidiaries, Medical International Technologies (MIT Canada) Inc. and 9139-2449 Quebec Inc. (dba Scanview). Intercompany
transactions and balances have been eliminated in consolidation.
Foreign
Currency Translations
The
Company operates out of its offices in Montreal, Canada and maintains its books and records in Canadian Dollars. The financial
statements herein have been converted into U.S. Dollars. Balance sheet accounts have been translated at exchange rates in effect
at the end of the year. Income statement accounts have been translated at average exchange rates for the year. Translation
gains and losses are included as a separate component of stockholders’ equity.
Cash
and Cash Equivalents
For
purpose of the statements of cash flows, the Company considers cash and cash equivalents to include cash on hand, amounts due
to banks and any other highly liquid investments with original maturities of three months or less.
Allowance
for Doubtful Accounts
The
allowance for doubtful accounts on accounts receivable is charged to income in amounts sufficient to maintain the allowance for
uncollectible accounts at a level management believes is adequate to cover any probable losses.
Management
determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable.
Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired.
MEDICAL
INTERNATIONAL TECHNOLOGY
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
YEARS
ENDED September 30, 2014 and 2013
Inventories
Inventories
are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. At each balance sheet
date, the Company evaluates its ending inventories for excess quantities and obsolescence. This evaluation includes an analysis
of sales levels by product type. Among other factors, the Company considers historical and forecasted demand in relation to the
inventory on hand, competitiveness of product offerings, market conditions and product life cycles when determining the net realizable
value of the inventory. Provisions are made to reduce excess or obsolete inventories to their estimated net realizable values.
Once established, write-downs are considered permanent adjustments to the cost basis of the excess or obsolete inventories.
Property
and Equipment
The
cost of property and equipment is depreciated over the estimated useful lives of the related assets, which range from 5 to 7
years. Depreciation is computed on the straight-line method. Depreciation expense for the years ended September 30, 2014 and
2013 was $61,327 and $121,599, respectively.
Long-Lived
Assets
FASB
Accounting Standards Codification 360-10-40, “Property, Plant, and Equipment, Impairment of Disposal of Long-Lived Assets”
(ASC 360-10-40), requires that long-lived assets, such as property and equipment and purchased intangibles subject to amortization,
be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be
recoverable. Recoverability of the asset is measured by comparison of its carrying amount to undiscounted future net cash flows
the asset is expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured as
the amount by which the carrying amount of the asset exceeds its fair market value. Estimates of expected future cash flows represent
our best estimate based on currently available information and reasonable and supportable assumptions. Any impairment recognized
in accordance with ASC 360-10-40 is permanent and may not be restored. As of September 30, 2014, we had not recognized any
impairment of long-lived assets in connection with ASC 360-10-40 based on our reviews.
Patents
Patents
on our technologies are being amortized over their remaining lives ranging from 6.5 years through 18 years.
Revenue
Recognition
The
Company recognizes revenue when the related product is shipped to the respective customer provided that: title and risk of loss
have passed to the customer; persuasive evidence of an arrangement exists; the sales price is fixed or determinable; and collectability
is deemed probable. Expenses are recognized in the period incurred.
Stock
options
Effective
October 1, 2005, we adopted the provisions of FASB Accounting Standards Codification 718, “Compensation —
Stock Compensation” (ASC 718), previously referred to as Statement of Financial Accounting Standards No. 123R, “Share-Based
Payment”. We adopted ASC 718 using the modified prospective transition method. Under this transition method,
compensation cost recognized includes (a) the compensation cost for all share-based awards granted prior to, but not yet
vested, as of October 1, 2005, based on the grant-date fair value estimated in accordance with the original provisions of ASC
718 and (b) the compensation cost for all share-based awards granted subsequent to September 30, 2005, based on the
grant-date fair value estimated in accordance with the provisions of ASC 718. Additionally, we accounted for restricted stock
awards granted using the measurement and recognition provisions of ASC 718. We measure the fair value of the restricted stock
awards on the grant date and recognize them in earnings over the requisite service period for each separately vesting portion
of the award.
The
Company determines the value of stock options utilizing the Black-Scholes option-pricing model. Compensation costs for share-based
awards with pro rata vesting are allocated to periods on a straight-line basis.
MEDICAL
INTERNATIONAL TECHNOLOGY
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
YEARS
ENDED September 30, 2014 and 2013
Net
Income (loss) per Common Share
Basic
earnings per share (“EPS”) are computed by dividing net loss by the weighted average number of common shares outstanding
for the period. Diluted EPS reflects the potential dilution from the exercise or conversion of securities into common stock, including
stock options and warrants. For the years ended September 30, 2014 and 2013, there were no dilutive effects of such securities
as the Company either had no potentially dilutive shares outstanding or had incurred a net loss in the period. At September
30, 2014, and 2013 the Company had no outstanding warrants or options to purchase common shares.
Use
of Estimates
The
preparation of financial statements in conformity with accounting principles generally accepted in the United States of America
requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses
during the reporting period. Actual results could differ from those estimates.
Income
Taxes
The
Company and its subsidiaries file a consolidated federal income tax return under the accrual method of accounting. The
Company accounts for income taxes under ASC 740-10-25. Under ASC 740-10-25, deferred tax assets and liabilities are
recognized for the future tax consequences attributable to temporary differences between the tax basis of assets and liabilities
and their carrying values for financial reporting purposes. When management determines that it is more than likely
that a deferred tax asset will not be realized, a valuation allowance is established. Deferred tax assets and liabilities are
measured using enacted tax rates expected to be recovered or settled. Deferred tax expense or benefit is the result of changes
in deferred tax assets and liabilities during the period. The effect on deferred tax assets and liabilities of
a change in tax rates is recognized as income in the period that includes the enactment date.
Effective
January 1, 2009, the Company adopted guidance regarding accounting for uncertainty in income taxes. This guidance clarifies the
accounting for income taxes by prescribing the minimum recognition threshold an income tax position is required to meet before
being recognized in the financial statements and applies to all federal or state income tax positions. Each income tax position
is assessed using a two step process. A determination is first made as to whether it is more likely than not that the income tax
position will be sustained, based upon technical merits, upon examination by the taxing authorities. If the income tax position
is expected to meet the more likely than not criteria, the benefit recorded in the financial statements equals the largest amount
that is greater than 50% likely to be realized upon its ultimate settlement. As of September 30, 2014 and 2013 there
were no amounts that had been accrued in respect to uncertain tax positions.
None
of the Company’s federal or state income tax returns is currently under examination by the Internal Revenue Service (“IRS”)
or state authorities.
Concentration
of Credit Risk
Financial
instruments that potentially subject the Company to concentrations of credit risk consist principally of cash in banks and trade
receivables. The Company manages this risk by maintaining all deposits in high quality financial institutions and periodically
performing evaluations of the relative credit standing of the financial institutions that are considered in the Company’s
investment strategy. The Company grants unsecured credit to its customers during the normal course of business and performs ongoing
credit evaluations of its customers to minimize any potential loss.
Fair
Value of Financial Instruments
The
Company’s financial instruments consist primarily of cash and cash equivalents, accounts receivable and accounts payable.
Management believes that the carrying values of these assets and liabilities are representative of their respective fair values
based on their short-term nature.
New
Accounting Pronouncements
The
Company does not expect recently issued accounting standards or interpretations to have a material impact on the Company’s
financial position, results of operations, cash flows or financial statement disclosures.
MEDICAL
INTERNATIONAL TECHNOLOGY
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
YEARS
ENDED September 30, 2014 and 2013
Note
3 – Inventories
Inventories
at September 30, 2014 and 2013 consist of the following:
| | |
2014 | | |
2013 | |
| Raw materials | |
$ | 195,838 | | |
$ | 216,053 | |
| Work in process | |
| 106,696 | | |
| 66,858 | |
| Finished goods | |
| 23,814 | | |
| 10,782 | |
| Total | |
$ | 326,348 | | |
$ | 293,693 | |
Note
4 – Patents
As
of September 30, 2014, the Company has net patents on certain technologies aggregating $58,226. Amortization expense for the years
ended September 30, 2014 and 2013 was $19,770 and $13,832, respectively. During the year ended September 30, 2014, the Company
capitalized patent costs on its needle-free injector of $6,465. Following is a detail of patents at September 30, 2014.
| | |
Gross
Intangible
Assets | | |
Accumulated
Amortization | | |
Net
Intangible
Assets | | |
Weighted
Average
Life
(Years) | |
| Patents | |
$ | 98,851 | | |
$ | 40,625 | | |
$ | 58,226 | | |
| 5 | |
Note
5 – Joint Venture Agreement
On
May 6, 2009, the Company entered into a certain joint venture agreement (the “Joint Venture Agreement”) with Jiangsu
Hualan Biotechnology Ltd. (China) (“Jiangsu Hualan”). Pursuant to the Joint Venture Agreement, the
parties established a joint venture company, Jiangsu Hualan MIT Medical Technology (MIT China) Ltd. (“MIT China” or
the “Joint Venture”), focusing on research, production and sales of medical equipments, import and export of medical
equipments and components products, especially Needle-Free Jet Injector products. The total investment by the Joint Venture shall
amount to $2,000,000, and the registered capital shall amount to $1,400,000. The Company invested cash of $426,678
and transferred the license rights to produce and sell the Company’s needle-free injectors products into the Joint Venture. The
license rights were valued at $280,000 under the agreement. The contributions by the Company resulted in the Company
owning 49% of the registered capital of the Joint Venture. Jiangsu Hualan contributed cash of $714,000, and owns 51%
of the registered capital.
Under
the agreement, the Company appointed 1 member to the Board of Directors of the Joint Venture and Jiangsu Hualan appointed 2
members to the Board of Directors. Profits of the Joint Venture will be paid based each parties investment in the registered
capital.
During
the period from May 6, 2009 to September 30, 2009, the Joint Venture had not commenced operations. The Joint Venture
commenced operations during the Company’s 1st quarter of fiscal 2010.
During
the third quarter of fiscal year 2011, MIT China purchased 151,000 sq. ft. of land and began construction of its first building
in Taizhou (China Medical City). This first building of 40,000 sq. ft. will be used for the production of injectors for the Chinese
market. The first stage (the offices) was completed and employees were moved into the facility in August 2012. The second
part of the construction is scheduled to be complete during the first quarter of 2013, which will contain the production facility
capable of supplying a large number of injectors and disposables to the Chinese market.
In
March 2012, MIT China agreed and sold 9% of the joint venture for an investment of 18,000,000 RMB (US$3,000,000). Jiangsu Hualan
now has 46.41%, the Company has 44.59%, and Taizhou Amazon Investment Center has 9% ownership in the MIT China joint venture.
MEDICAL
INTERNATIONAL TECHNOLOGY
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
YEARS
ENDED September 30, 2014 and 2013
The
Company accounts for its investment in MIT China in accordance with Financial Accounting Standards Board Accounting Standards
Codification 323, “Investment — Equity Method and Joint Venture” (ASC 323), Accordingly, the Company adjusts
the carrying amount of its investment in MIT China to recognize its share of earnings or losses. As of September 30, 2014, the
Company had no recorded investment in the MIT China. During the year ended September 30, 2014, the Company had no recorded equity
income or loss from its investment in MIT China.
During
the year ended September 30, 2014, the Company had $76,931 in sales of products to the joint venture.
During
the year ended September 30, 2013, the Company had $296,350 in sales of products to the joint venture.
Note
6 – Line of Credit
The
Company, through a hypothec agreement, has a line of credit up to a maximum of $100,000. The line is secured by Investissement
Quebec (a Quebec government entity) and by Karim Menassa (personally) and by account receivables, inventories, equipment and all
other assets of the Company. The line bears interest at the prime rate plus 2.5% (5.75% at September 30, 2014). At September 30,
2014 and 2013, the Company had $71,376 and $63,200 outstanding under the agreement.
Note
7 – Related Party Transactions
As
of September 30, 2014, the Company had two unsecured notes due to related parties of $30,000 that bear interest at 8% and are
due December 15, 2015.
As
of September 30, 2014, the Company had an unsecured advance from a shareholder of $50,000. This advance bears no interest and
was converted to 500,000 common shares as of October 2014.
During
2014 and 2013, the Company paid approximately $133,000 and $185,000, respectively to a company owned by the President and CEO
for consulting fees.
As
of September 2013, the Company had no amounts due to related parties.
Note
8 – Income Taxes
Deferred
income taxes are provided for the tax effects of temporary differences in the reporting of income for financial statement and
income tax reporting purposes and arise principally from net operating loss carry-forwards, accrued expenses and basis differences
in fixed assets.
The
Company’s effective tax rate differs from the Federal statutory rates due to the valuation allowance recorded for the unused
net operating loss carry-forwards deferred tax asset. The company has operating losses aggregating approximately $12.3 million,
which can be used to reduce future taxable income. Pursuant to ASC 740, we must consider all positive and negative evidence regarding
the realization of deferred tax assets, including past operating results and future sources of taxable income. Under the provisions
of ASC 740, we determined that the entire net deferred tax asset needed to be reserved given recent losses. The total valuation
allowance at September 30, 2014 and 2013 was $12.3 million and $12.2 million, respectively.
We
have adopted the provisions of FIN 48, now under ASC 740. Under ASC 740, the impact of an uncertain tax position taken or
expected to be taken on an income tax return must be recognized in the financial statements at the largest amount that is more-likely-than-not
to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized in the financial
statements unless it is more likely than not of being sustained.
MEDICAL
INTERNATIONAL TECHNOLOGY
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
YEARS
ENDED September 30, 2014 and 2013
Note
9 – Stockholders’ Equity (Deficit)
Issuance
of Common Stock
Year
Ended September 30, 2014
From
time to time, the Company will issue common stock for services rendered, debt reductions or as part of private placement offerings.
For
the year ended September 30, 2014, there were no common stock issuances.
Year Ended September 30, 2013
For
the year ended September 30, 2013, there were no common stock issuances.
Preferred
Stock
As
of September 30, 2014, there was no preferred stock outstanding. Dividend features and voting rights are at the discretion of
the Board of Directors without the requirement of shareholder approval.
Outstanding
Options
As
of September 30, 2014 and 2013, there are no options outstanding to purchase shares of the Company’s common stock.
Outstanding
Warrants
As
of September 30, 2014 and 2013, there are no warrants outstanding to purchase shares of the Company’s common stock.
Note
10 – Operating Leases
The
Company leases its office and warehouse space under an operating lease that expires on December 31, 2014. The company
has negotiated an extension for one more year until December 31, 2015 at the same rent amount and conditions of 2014. The
lease calls for a monthly rent of $4,248 (CND) Rent expense for the years ended September 30, 2014 and 2013 was approximately
$47,600 and $51,000, respectively.
Future
minimum lease commitments pertaining to the lease in Canadian Dollars areas follows:
| Year ended | |
|
| | |
|
| | September 30, 2015 | | |
$ | 51,000 | |
| | | | |
| | |
| | September 30, 2016 | | |
$ | 12,800 | |
| | | | |
| 63,800 | |
MEDICAL
INTERNATIONAL TECHNOLOGY
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
YEARS
ENDED September 30, 2014 and 2013
Note
11– Deferred Income
On
November 1, 2007, the Company received a deposit of $1,300,000 for the worldwide rights to market and sells while maintaining
MIT CANADA right to sell all Medical International Technology Inc.’s Needle-Free Jet-Injectors for the human and animal
markets. This deposit was part of an agreement under negotiation, which was finalized in January 2009. Upon finalization,
the Company began recognizing the deposit into income over the contractual life of the agreement. During the year ended September
30, 2010, the Company recognized $130,000 into income under this agreement. During 2011, the Company was notified of
potential litigation related to this contract. Accordingly, due to the uncertainty in a final resolution, the Company
ceased recognizing income related to this contract during 2011.
During
the fourth quarter of fiscal 2013, the Company successfully defended itself from litigation related to this agreement. Upon
closure of the litigation, it was determined the Company had no further obligations under the original agreement, nor did the
Company have any obligation to repay any portion of the original deposit. Accordingly, the Company recognized the outstanding
deferred income amount of $1,072,500 as a one-time charge to other income on the accompanying statement of operations.
Note
12 – Notes Payable
Long-term
debt consists of the following at September 30, 2014 and 2013:
| | |
September 30,
2014 | | |
September 30,
2013 | |
| Note payable to a bank, bearing interest at prime plus 3% (6.25% at September 30, 2014), secured by equipment, due December 20, 2016. | |
$ | 55,572 | | |
$ | 89,194 | |
| Loan Canada Economic Development, no interest, repayment of the contribution in sixteen (16) Equal and consecutive quarterly installments of $5,035 (CND) through May 2016 | |
| 31,448 | | |
| 53,854 | |
| Total long-term debt | |
| 87,020 | | |
| 143,048 | |
| Current portion of long-term debt | |
| (44,222 | ) | |
| (51,442 | ) |
| | |
| | | |
| | |
| Long-term debt, net of current portion | |
$ | 42,798 | | |
$ | 91,606 | |
Future
scheduled principal payments under the note agreements are as follows:
| Year ended | |
| |
| | |
| |
| September 30, 2016 | |
$ | 39,733 | |
| | |
| | |
| September 30, 2017 | |
| 3,065 | |
| | |
| 42,798 | |
Note
13 – Contingencies
Legal
Proceedings
We
are currently not involved in any litigation that we believe could have a material adverse effect on our financial condition or
results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government
agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our company or any of our
subsidiaries, threatened against or affecting our company, our common stock, any of our subsidiaries or of our companies or our
subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse
effect.
Note
14 – Subsequent Events
On
October 28, 2014, the Company issued 500,000 shares of its common stock for payment of the $50,000 advance from related party.
Item
9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
None.
Item
9A. Controls and Procedures
Evaluation
of Disclosure Controls and Procedures
Pursuant
to Rule 13a-15(b) under the Securities Exchange Act of 1934 (“Exchange Act”), the Company carried out an evaluation,
with the participation of the Company’s management, including the Company’s Chief Executive Officer (“CEO”)
and Chief Financial Officer (“CFO”) (the Company’s principal financial and accounting officer), of the effectiveness
of the Company’s disclosure controls and procedures (as defined under Rule 13a-15(e) under the Exchange Act) as of the end
of the period covered by this report. Based upon that evaluation, the Company’s CEO and CFO concluded that the Company’s
disclosure controls and procedures are effective to ensure that information required to be disclosed by the Company in the reports
that the Company files or submits under the Exchange Act, is recorded, processed, summarized and reported, within the time periods
specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the Company’s
management, including the Company’s CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure.
Management's
Annual Report on Internal Control over Financial Reporting.
The
management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting for
the Company. Our internal control system was designed to, in general, provide reasonable assurance to the Company’s
management and board regarding the preparation and fair presentation of published financial statements, but because of its inherent
limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of
any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes
in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Our
management assessed the effectiveness of the Company’s internal control over financial reporting as of September 30, 2014. The
framework used by management in making that assessment was the criteria set forth in the document entitled “ Internal Control
– Integrated Framework” issued by the Committee of Sponsoring Organizations of the Tread way Commission. Based on
that assessment, our management has determined that as of September 30, 2014, the Company’s internal control over financial
reporting was effective for the purposes for which it is intended.
This
annual report does not include an attestation report of the Company’s registered public accounting firm regarding internal
control over financial reporting. Management's report was not subject to attestation by the Company's registered public accounting
firm pursuant to temporary rules of the Securities and Exchange Commission that permit the Company to provide only management's
report in this annual report.
Changes
in Internal Control over Financial Reporting
No
change in our system of internal control over financial reporting occurred during the period covered by this report, the fourth
quarter of the fiscal year ended September 30, 2014 that has materially affected, or is reasonably likely to materially affect,
our internal control over financial reporting.
Item
9B. Other Information
None.
PART
III
Item
10. Directors, Executive Officers, and Corporate Governance
Our
directors and executive officers are as follows:
| Name
and Address |
|
Age
|
|
Position(s)
|
| Karim Menassa |
|
63 |
|
President, Chief Executive Officer, Chief
Financial Officer, interim Secretary, Director. |
| |
|
|
|
Principal Financial Officer, Principal
Accounting Officer and Director |
Mr.
Karim Menassa, 63, serves as the President, Chief Executive Officer, Chief Financial Officer, and interim Secretary
of the Company since June 27, 2002. Mr. Menassa also serves as a member of the Board of Directors of the Company. Mr. Menassa
has developed many state-of-the-art, efficient and reliable devices, and has marketed various medical devices in more than 60
countries. Mr. Menassa obtained a degree in Precision Mechanics Design from the Instituto Salesiano Don Bosco in Cairo,
Egypt.
Over
the years he has gained a vast and varied experience as an entrepreneur, administrator and medical device product innovator. He
has established a significant bank of important and influential contacts in Canada and abroad, touching all aspects of a modern
manufacturing industry. His particular strengths are in administration, engineering, product development, and marketing. He is
also extremely skilled in international negotiations, having successfully negotiated several multimillion dollar contacts and
established distributor relationships in over 60 countries. Some major achievements in his career include:
| ● |
Inventor of needle-free jet
injector for diabetics |
| |
|
| ● |
Inventor of needle-free jet injector
for veterinary use |
| |
|
| ● |
Inventor of semi-automatic assembly station |
| |
|
| ● |
Founder of IDEE International R &
D Inc. in 1984 |
| |
|
| ● |
Founder of IDEE Technologies Inc. in
1985 |
| |
|
| ● |
Founder of Alliance Medical Inc. in 1989 |
| |
|
| ● |
Founder of Medical International Technologies
(MIT Canada) inc. in 2002 |
Involvement
in Certain Legal Proceedings
To
the best of our knowledge, none of our directors or executive officers has been convicted in a criminal proceeding, excluding
traffic violations or similar misdemeanors, or has been a party to any judicial or administrative proceeding during the past ten
years that resulted in a judgment, decree, or final order enjoining the person from future violations of, or prohibiting activities
subject to, federal or state securities laws, or a finding of any violation of federal or state securities laws, except for matters
that were dismissed without sanction or settlement. Except as set forth in our discussion below in “Certain Relationships
and Related Transactions, and Director Independence – Transactions with Related Persons,” none of our directors, director
nominees, or executive officers has been involved in any transactions with us or any of our directors, executive officers, affiliates,
or associates which are required to be disclosed pursuant to the rules and regulations of the Commission.
Board
of Director Meetings and Committees
The
directors shall be elected at an annual meeting of the stockholders and except as otherwise provided within the Bylaws of Medical
International Technology, Inc., as pertaining to vacancies, shall hold office until his successor is elected and qualified.
The
Board of Directors held no meetings during the year ended September 30, 2014, but conducted board activities through unanimous
consent board resolutions in lieu of meetings.
Our
Board of Directors has no separate committees and our Board of Directors acts as the audit committee and the compensation committee.
We do not have an audit committee financial expert serving on our Board of Directors.
Section
16(a) Beneficial Ownership Reporting Compliance
Section
16(a) of the Securities Exchange Act of 1934 requires the company’s directors and officers, and persons who own more than
ten-percent (10%) of the company’s common stock, to file with the Securities and Exchange Commission reports of ownership
on Form 3 and reports of change in ownership on Forms 4 and 5. Such officers, directors and ten-percent stockholders are also
required to furnish the company with copies of all Section 16(a) reports they file. Based solely on its review of the copies of
such forms received by the company and on written representations from certain reporting persons, the company believes that all
Section 16(a) reports applicable to its officers, directors and ten-percent stockholders with respect to the fiscal year ended
September 30, 2014 were filed.
Code
of Ethics
We
have adopted a code of ethics that applies to our principal executive officer, principal financial officer, principal accounting
officer or controller, or persons performing similar functions. The code of ethics is designed to deter wrongdoing
and to promote:
| ● |
Honest
and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional
relationships; |
| |
|
| ● |
Full,
fair, accurate, timely, and understandable disclosure in reports and documents that we file with, or submit to, the SEC and
in other public communications made by MIT; |
| |
|
| ● |
Compliance
with applicable governmental laws, rules and regulations; |
| |
|
| ● |
The
prompt internal reporting of violations of the code to an appropriate person or persons identified in the code; and |
| |
|
| ● |
Accountability
for adherence to the code. |
We
will provide to any shareholder, upon request, a copy of our code of ethics. Any such request should be directed to
our corporate secretary at 1872 Beaulac, Ville Saint Laurent, Montreal, Quebec, Canada HR4 2E7.
Item
11. Executive Compensation
Compensation
Summary
The
following executives of the Company received compensation in the amounts set forth in the chart below for the fiscal years ended
September 30, 2014 and 2013. No other item of compensation was paid to any officer or director of the Company other than reimbursement
of expenses.
EXECUTIVE
OFFICER COMPENSATION TABLE
Name and Principal Position | |
Year | | |
Salary ($) | | |
Bonus ($) | | |
Stock Awards ($) | | |
Option Awards ($) | | |
Non-Equity Incentive Plan Compensation ($) | | |
Non-Qualified Deferred Compensation Earnings ($) | | |
All Other Compensation ($) | | |
Totals ($) | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| |
| Karim Menassa, CEO, President, CFO. | |
| 2014 | | |
$ | 0 | | |
| 0 | | |
| 0 | | |
| 0 | | |
| 0 | | |
| 0 | | |
| 0 | | |
$ | 0 | |
| Interim Secretary and Chairman of the Board | |
| 2013 | | |
$ | 0 | | |
| 0 | | |
| 0 | | |
| 0 | | |
| 0 | | |
| 0 | | |
| 0 | | |
$ | 0 | |
As
of September 30, 2014, the Company had no group life; health, hospitalization, medical reimbursement or relocation plans in effect.
Further, we had no pension plans or plans or agreements which provide compensation on the event of termination of employment or
change in control of us.
Compensation
of Directors
We
do not pay members of our Board of Directors any fees for attendance or sireurse them for any out-of-pocurred by them in connection with our business.
Employment
Agreements
No
formal employment agreements exist with any officer or employee.
Long-Term
Incentive Plan
The
Company has a 2014 stock incentive plan under which directors are authorized to grant incentive stock options, to a maximum of
five million (5,000,000) of the issued and outstanding shares, to directors, employees and consultants of the Company. The plan
provides both for the direct award or sale of shares and for the grant of options to purchase shares. There are no
shares issued or outstanding under the plan.
Item
12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
The
following table sets forth certain information as of September 30, 2014 with respect to the holdings of: (1) each person known
to us to be the beneficial owner of more than 5% of our common stock; (2) each of our directors, nominees for director and named
executive officers; and (3) all directors and executive officers as a group. To the best of our knowledge, each of the persons
named in the table below as beneficially owning the shares set forth therein has sole voting power and sole investment power with
respect to such shares, unless otherwise indicated.
| |
Amount and
Nature of | | |
Percent of | |
Name and Address
Of Beneficial Holder | |
Beneficial Ownership | | |
Common Stock (1) | |
| | |
| | |
| |
| Karim Menassa (2) | |
| 34,135,692 | | |
| 40.73 | % |
| President, CEO, CFO, Director | |
| | | |
| | |
| 1872 Beaulac, Ville Saint-Laurent | |
| | | |
| | |
| Montreal, Quebec, Canada HR4 2E7 | |
| | | |
| | |
| | |
| | | |
| | |
| The Estate of Michel Bayouk | |
| 4,522,560 | | |
| 5.39 | % |
| 1872 Beaulac, Ville Saint-Laurent | |
| | | |
| | |
| Montreal, Quebec, Canada HR4 2E9 | |
| | | |
| | |
| | |
| | | |
| | |
| Sun Yi | |
| 4,928,576 | | |
| 5.88 | % |
| 13 Building 6 Renmin University | |
| | | |
| | |
| #175 Haidian Road, HaidianDist.A | |
| | | |
| | |
| Beijing, China | |
| | | |
| | |
| | |
| | | |
| | |
| Les Consultants RainvilleTossounian& Associes Inc. | |
| 5,192,000 | | |
| 6.19 | % |
1585 ST LOUIS, ST LAZARE
QUEBEC, J7T-1Z1, Canada | |
| | | |
| | |
| Officers and Directors as a Group | |
| 34,135,692 | | |
| 40.73 | % |
(1)
Based on 83,804,627 shares issued and outstanding as of September 30, 2014.
(2)
Karim Menassa directly holds 2,787,422 common shares of the Company, indirectly holds: (i) 21,466 shares through Paulette Menassa,
his wife, (ii) 16,285,139 shares through 2849674 Canada, Inc., (iii) 13,666,667 shares through Idee R&D International,
Inc., and 9 iv) 1,375,000 shares through 9162-9725 Quebec Inc., which are all controlled by Karim Menassa.
Changes
in Control
We
are not aware of any person who owns of record, or is known to own beneficially, five percent or more of our outstanding securities
of any class, other than as set forth above. We do not have an investment advisor. There are no current arrangements
which will result in a change in control, other than those set forth above.
Director
Independence
We
do not have any independent directors. Because our common stock is not currently listed on a national securities exchange, we
have used the definition of “independence” of The NASDAQ Stock Market to make this determination. NASDAQ
Listing Rule 5605(a) (2) provides that an “independent director” is a person other than an officer or employee of
the company or any other individual having a relationship which, in the opinion of the company’s Board of Directors, would
interfere with the exercise of independent judgment in carrying out the responsibilities of a director. The NASDAQ
listing rules provide that a director cannot be considered independent if:
| ● |
The
director is, or at any time during the past three years was, an employee of the company; |
| |
|
| ● |
The director or
a family member of the director accepted any compensation from the company in excess of $120,000 during any period of 12 consecutive
months within the three years preceding the independence determination (subject to certain exclusions, including, among other
things, compensation for board or board committee service); |
| |
|
| ● |
a
family member of the director is, or at any time during the past three years was, an executive officer of the company; |
| |
|
| ● |
the director or a family member of the
director is a partner in, controlling stockholder of, or an executive officer of an entity to which the company made, or from
which the company received, payments in the current or any of the past three fiscal years that exceed 5% of the recipient’s
consolidated gross revenue for that year or $200,000, whichever is greater (subject to certain exclusions); |
| |
|
| ● |
the
director or a family member of the director is employed as an executive officer of an entity where, at any time during the past
three years, any of the executive officers of the company served on the compensation committee of such other entity; or |
| |
|
| ● |
The director or a family member of the
director is a current partner of the company’s outside auditor, or at any time during the past three years was a partner
or employee of the company’s outside auditor, and who worked on the company’s audit. |
Mr.
Menassa is not considered to be independent because he is an executive officer of the Company.
We
do not currently have a separately designated audit, nominating or compensation committee.
Item
14. Principal Accounting Fees and Services
Audit
Fees
The
aggregate fees billed for each of the last two fiscal years for professional services rendered by the principal accountant for
the audit of the registrant's annual financial statements and review of financial statements included in the registrant's Form
10-Q or services that are normally provided by the accountant in connection with statutory and regulatory filings or engagements
for the fiscal years ending September 30, 2014 and 2013 were: $15,000 and $15,500 respectively.
Audit
Related Fees
There
were no fees for audit related services for the years ended September 30, 2014 and 2013.
Tax
Fees
The
Company did not incur any fees for the fiscal years ended September 30, 2014 and 2013 for professional services rendered for tax
compliance, tax advice, and tax planning.
All
Other Fees
The
Company did not incur any other fees related to services rendered by our principal accountant for the fiscal years ended September
30, 2014 and 2013.
Audit
Committee
The
registrant's Audit Committee, or officers performing such functions of the Audit Committee, have approved the principal accountant's
performance of services for the audit of the registrant's annual financial statements and review of financial statements included
in the registrant's Form 10-Q or services that are normally provided by the accountant in connection with statutory and regulatory
filings or engagements for the fiscal year ending September 30, 2014. Audit-related fees, tax fees, and all other fees, if any,
were approved by the Audit Committee or officers performing such functions of the Audit Committee.
Work
Performance by Others
None.
PART
IV
Item
15. Exhibits
| 31.1 | |
Certification of Principal Executive Officer and the Principal Financial Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| | |
|
| 32.1 | |
Certification of Principal Executive Officer and the Principal Financial Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 101.SCH | |
XBRL Taxonomy Schema |
| 101.CAL | |
XBRL Taxonomy Calculation Linkbase |
| 101.DEF | |
XBRL Taxonomy Definition Linkbase |
| 101.LAB | |
XBRL Taxonomy Label Linkbase |
| 101.PRE | |
XBRL Taxonomy Presentation Linkbase |
In
accordance with SEC Release 33-8238, Exhibit 32.1 is being furnished and not filed.
SIGNATURES
Pursuant
to the requirements of Section 13 or 15 (d) of the Securities Exchange Act of 1934, the registrant had duly caused this report
to be signed on its behalf to the undersigned, thereunto duly authorized.
| |
Medical International
Technology, Inc. |
| |
|
|
| Date: November 18th, 2015 |
By: |
/s/ Karim
Menassa |
| |
|
Karim Menassa |
| |
|
President
and Principal Executive Officer,
Principal
Financial Officer, interim Secretary,
Director
(Duly Authorized Principal Executive
Officer
and Principal Financial Officer) |
Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed as of the 18th day of
November, 2015 by the following persons on behalf of the registrant in the capacities indicated:
| /s/
Karim Menassa |
|
President
and Principal Executive Officer, Principal Financial Officer, interim Secretary, Director |
| Karim Menassa |
|
|
42
Exhibit 31.1
CERTIFICATION
OF PRINCIPAL EXECUTIVE OFFICERAND
PRINCIPAL FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 302
OF
THE SARBANES-OXLEY ACT OF 2002
I, Karim Menassa, certify that:
| 1. |
I have reviewed this annual report on Form 10-K of Medical International Technology, Inc.; |
| 2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
| 3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
| 4. |
As the registrant's certifying officer, I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and I have: |
| a) |
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
| b) |
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
| c) |
evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
| d) |
disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting. |
| 5. |
As the registrant's certifying officer, I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function): |
| a) |
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and |
| b) |
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
| |
Medical International Technology, Inc. |
| |
|
|
| Date: November 18, 2015 |
By: |
/s/ Karim Menassa |
| |
|
Karim Menassa |
| |
|
President and Chief Executive Officer and |
| |
|
Chief Financial Officer
(Principal Executive Officer and Principal Financial Officer) |
Exhibit 32.1
CERTIFICATION
OF PRINCIPAL EXECUTIVE OFFICER AND
PRINCIPAL FINANCIAL OFFICER
PURSUANT TO 18 U. S. C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY
ACT OF 2002
In connection with the Annual Report
of Medical International Technology, Inc. (the "Company") on Form 10-K for the fiscal year ending September 30,
2014, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Karim Menassa, President,
Chief Executive Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
| (1) |
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| (2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
| |
Medical International Technology, Inc. |
| |
|
|
| Date: November 18,
2015 |
By: |
/s/ Karim Menassa |
| |
|
Karim Menassa |
| |
|
President, Chief Executive Officer and |
| |
|
Chief Financial Officer
(Principal Executive Officer and Principal Financial Officer) |
Medical International Te... (CE) (USOTC:MDLH)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Medical International Te... (CE) (USOTC:MDLH)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
